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Zusammenfassung
Das Ziel dieser Arbeit war es, die Rolle von Creld2 bei der Aufrechterhaltung der
metabolischen Homöostase unter Normalbedingungen und bei der Regulation der
UPR unter ER Stressbedingungen zu untersuchen. Metabolische Analysen von
Creld2-/- Mäusen zeigten eineAnfälligkeit von 1-jährigen Männchen für die Entwicklung
von Hepatosteatose und Insulinresistenz, wleche von einer fehlregulierten Pgc1α
Genexpression und einer reduzierten Genexpression der Glukosetransporter Glut2
und Glut4 begleitet wird. Weibliche Creld2-/- Mäuse sind wahrscheinlich aufgrund
geschlechtsspezifischer Hormonregulationsunterschiede vor Lebersteatose geschützt.
In vitro-ER-Stressanalysen von Wildtyp und Cred2-defizienten MEFs zeigten, dass
Creld2-/- -Zellen den entstehenden Stress nicht so gut wie Creld2+/+-Zellen tolerieren
können und folglich apoptotisch werden, wenn sie mit ER-Stress konfrontiert
werden. Eingehende Analysen der drei UPR-Signalwege zeigten eine verzögerte
und mangelhafte Antwort von Creld2-/--Zellen auf ER-Stress, wleches zu einem
unvollständigen ER-Stressabbau und zur Akkumulation von ER-Stress führt, was
die funktionalität der Zellen beeinträchtigt. Diese in vitro-Ergebnisse stützen die
Hypothese, dass das Fehlen von Creld2 zu nicht aufgelöstem ER-Stress und der
nachfolgenden Entwicklung von Lebersteatose führt. Darüber hinaus zeigen die
Co-Präzipitationsstudien von Creld2 eine Bereicherung zahlreicher Faltungsproteine
und Proteinen, welche am Kohlenhydratstoffwechsel beteiligt sind auf. Dies deutet
darauf hin, dass Creld2 mit solchen Proteinen interagiert und dadurch deren Funktion
beeinflussen könnte. Schlussfolgernd deuten die Ergebnisse dieser Arbeit darauf hin,
dass Creld2 an der Regulation von Stoffwechselprozessen beteiligt ist, indem es eine
angemessene ER-Stressantwort, durch die zeitliche Koordination und Verstärkung des
UPRs, ermöglicht.
”The most beautiful experience we can have is the mysterious. It is the fundamental
emotion that stands at the cradle of true art and true science”
–Albert Einstein–
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1 Introduction
1.1 Cysteine-rich with EGF-like domains family
The cysteine-rich with EGF-like domains (Creld) 2 gene was identified early this
century as a homologue of Creld1, the other member of the Creld protein family. In
human, these proteins exhibit 38% identity and 51% similarity [1]. Proteins of the
Creld family are highly conserved across species and possess an N-terminal signal
peptide for endoplasmic reticulum (ER) localisation followed by a unique tryptophane
(W) and glutamic acid (E)-rich domain (WE domain) including a highly conserved
nonapeptide. Following the WE domain, Creld family proteins exhibit an array of one or
two epidermal growth factor (EGF)-like and Ca2+ binding EGF-like domains, depending
on the species. The significant difference between Creld1 and Creld2 is the presence
of transmembrane domains in Creld1, which are absent in Creld2. Although Creld1
and Creld2 display high domain homology, the presence or absence of a membrane
anchoring renders these proteins very diverse in their functions [1,2].
1.2 Creld1
Creld1 is repeatedly found to be mutated in atrioventricular septal defect (AVSD)
patients and thus was characterised as an AVSD risk factor [3–6]. Analysis of Creld1
function showed that Creld1 effects heart development by enhancing nuclear factor of
activated T cells 1 (NFATc1) nuclear localisation, thereby contributing to atrioventricular
septum formation [7].
1.3 Creld2
The Creld2 protein is highly conserved between species, such as human, mouse,
rat, zebrafish and Drosophila melanogaster, with human and murine Creld2 displaying
highest conservation. The length or integrity of theWE domain and the presence of one
or two Ca2+-binding EGF-like domains are the major differences in the primary Creld2
protein structures. Creld2 was shown to be a glycoprotein [8], and differences in the
predicted sites for N-glycosylation are visible between species. Minor alterations in the
1
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Figure 1.1: Predicted Creld2 protein structure is conserved between different species.
Comparison of Creld2 primary protein structure in different species. From N- to C-terminus:
Signal peptide (black), WE-domain differing in length between species (yellow) containing a
conserved nonapeptide (GGNTAWEE E/K/R; orange). Followed by an epidermal growth factor
(EGF)-like/laminin-type (green) and one or two Ca2+-binding EGF-like (red) and an ER retention
signal peptide at the very C-terminus (REDL, HEDL, HEEL or KDEL). EGF-like domains contain
the six characteristic disulfide bonds (olive green rectangles). Predicted sites for N-glycosylation
are indicated (N-Glc). For human Creld2 only the main isoform is illustrated.
amino acid sequence of the nonapeptide (GGNTAWEE E/K/R), which is enclosed in the
WE domain, and in the ER-retention motif sequence are present (Figure 1.1). Here,
the human Creld2 isoform 1 and murine Creld2 display the highest conservation. While
there is only one Creld2 isoform present in mouse, the human genome encompasses
six Creld2 transcripts due to alternative splicing. This results in six human Creld2
isoforms, which mainly differ in the spacing and presence or absence of EGF-like
and Ca2+-binding domains. One isoform, however, is missing the ER retention motif.
Nevertheless, the dinstinctive WE domain is present in all isoforms [9].
Creld2 shows ubiquitous expression and displays highest expression levels in secretory
organs, for instance, the liver, pancreas, kidney and thyroid gland. [9]. Primarily, Creld2
localises in the ER due to its ER retention signal sequence, but Creld2 secretion to
2
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the extracellular space is increased during ER stress or by the absence or masking of
the ER retention sequence [8]. Creld2 promoter analyses identifiedf a conserved ER
stress response element (ERSE) sequence. This ERSE sequence was shown to be
bound by the activating transcription factor 6 (ATF6) resulting in the induction of Creld2
expression [10]. Recently, Creld2 was identified as a new urinary biomarker for various
aberrant kidney states, for instance, acute kidney injury and tubulointerstitial kidney
disease [11].
First molecular analyses indicated that Creld2 binds the neuronal nicotinic acetylcholine
receptor α4 and β2 subunits, which suggests the involvement of Creld2 in protein
folding and transport to the plasma membrane [12]. Additionally, several implications
of Creld2 involvement in bone growth and homeostasis were reported, which are
elucidated in section 1.7.
1.4 ER stress and the unfolded protein response
Cells have a constant need to produce proteins for the maintenance of metabolic
homeostasis, proliferation or secretion of hormones and other signalling molecules.
Proteins anchored to the membrane or those destined for secretion need to be
correctly folded and glycosylated in the ER. However, dysregulations of Ca2+ levels,
glucose deficiency or merely a demand for a vast amount of proteins can lead to the
accumulation of unfolded proteins because these cannot be properly folded in time.
This accumulation and the resulting aggregation of proteins is termed ER stress and
is markedly elevated in organs with high protein turnover, such as the liver, kidney and
pancreas [13]. To resolve emerging ER stress, the cell elicits a stringently controlled
program called the unfolded protein response (UPR) [14].
ER stress in the cell is detected by three ER-transmembrane stress sensors, namely
PRKR-like endoplasmic reticulum kinase (Perk), Atf6 and inositol-requiring protein 1
α (Ire1α), which evoke and orchestrate UPR pathways to ameliorate the ER stress
once they are activated. Here, the three UPR branches induce transcriptional programs
either independently or in a cooperative manner (Figure 1.2) [15, 16]. In principle, the
UPR resolves ER stress by reducing the protein load to the ER, increasing the folding
capacity and boosting degradation of ultimately misfolded proteins. Under homeostatic
3
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conditions, the three stress sensors are bound and deactivated by the ER stress master
regulator chaperone 78 kDa glucose-regulated protein (Grp78). In case of emerging
ER stress, Grp78 releases the sensors in order to bind and fold non-native proteins.
This, in turn, leads to an activation of the sensors, which initiate the UPR [17]. If the cell
does not succeed to eliminate the ER stress, the cell activates pathways responsible
for ER stress-mediated apoptosis [18].
1.4.1 The Perk pathway
Dissociation of Grp78 from Perk leads to Perk dimerisation and autophosphorylation
and renders it active. Then, Perk phosphorylates and thereby inactivates the eukaryotic
initiation factor 2 α (eIF2α). Inactivation of eIF2α, in turn, results in a global
attenuation of protein synthesis and reduces protein flux to the ER. Inhibition of
eIF2α leads to selective translation of certain proteins. One of these proteins is
the activating transcription factor 4 (Atf4), which contains an internal ribosomal entry
site (IRES) and induces the expression of genes important to relieve ER stress,
thereby reducing reactive oxygen species (ROS) production. The growth arrest and
DNA damage-inducible protein (Gadd34) is one of these important factors. Gadd34
dephosphorylates P-eIF2α and leads to a normalisation of protein synthesis [19, 20].
However, if the ER is perturbed for extended periods, the prolonged induction of
CCAAT-enhancer-binding protein homologous protein (Chop) by Atf4 results in ER
stress-induced apoptosis of the cell [21,22].
1.4.2 The Atf6α pathway
Inactive Atf6α is bound by Grp78. Activation of the Atf6α branch starts with
the detachment of Grp78 from Atf6α. Subsequently, Atf6α is translocated to the
Golgi-apparatus where it is proteolytically cleaved by site-1 protease (S1P) and
site-2 protease (S2P), which leads to the release of the cytoplasmic and active
transcription factor Atf6α form, termed nuclear Atf6α (nAtf6α) [23]. nAtf6α was shown
to induce gene expression of sets of chaperones, ER-associated protein degradation
(ERAD) components and other genes involved in protein folding and glycosylation.
Known downstream targets are Grp78, Grp94, Chop, ER degradation enhancing
alpha-mannosidase like protein 1 (Edem1),Derlin 3 (Derl3) andCreld2 [10,24]. Further,
4
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it was shown that for full activation of this UPR branch, nAtf6α dimerises and induces
gene expression with the transcription factor spliced X-box binding protein 1 (sXbp1)
[25]. Overexpression of Creld2 in NIH3T3 fibroblasts triggers a selective up-regulation
of the ER stress-inducible gene Chop and an increase of Xbp1 splicing, while other
ER stress-related genes, such as Grp78, Atf6α or Gadd34 remained unaltered in
expression levels [2].
1.4.3 The Ire1α pathway
For the activation of Ire1α and induction of its downstream target genes, Ire1α
undergoes dimerisation and trans-autophosphorylation after detachment from Grp78
[26]. When active, Ire1α exerts its endoribonuclease activity and splices Xbp1 mRNA,
which then results in the active transcription factor sXbp1 [27]. sXbp1 was shown to
induce genes involved in protein folding [28] and ERAD [29]. However, as mentioned
above, sXbp1 executes its functionality to a large extent in combination with nAtf6α.
1.5 UPR signalling & disease
The UPR is an essential control machinery for virtually all cells in an organism since
every living cell requires a homeostatic metabolism involving the synthesis, proper
folding, potential secretion of proteins as well as an accurate sensing of non-native
proteins. If the quality control is impaired either in recognising ER stress or in eliciting
the appropriate responses, the cells’ metabolism will eventually become imbalanced
Figure 1.2 (preceding page): Overview of the unfolded protein response. ER stress
sensors Atf6α, Ire1αand Perk are bound and inactivated by Grp78 under non-stressed
condidions. When unfolded proteins accumulate in the ER causing ER stress, Grp78
dissociates from the ER stress sensors to assist in folding, thereby leading to activation
of these sensors. (From left to right) Activation of Atf6α leads to its translocation to the
Golgi-apparatus where it is proteolytically cleaved, releasing the active transcription factor
nAtf6α . Subsequently, nAtf6α induces gene expression of chaperones (e.g. Grp78 and
Grp94), components of the ERADmachinery (e.g. Edem1 and Derl3), Creld2 and Chop. Grp78
dissociation from Ire1α triggers Ire1α dimerization and trans-autophosphorylation initiating
its endoribonuclease activity. Ire1α splices Xbp1 resulting in the active transcription factor
sXbp1, which induces gene expression of various ERAD machinery components. Perk
dimerises and trans-autophosphorylates after Grp78 detachment. Active Perk inactivates eIF2α
by phosphorylation leading to attenuation of global protein synthesis resulting in selective
translation ofAtf4, which inducesGadd34 andChop gene expression. Gadd34 reverts inhibition
of eIF2α by dephosphorylating it.
6
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leading to aberrant or senescent regulation of metabolic processes and result in
apoptosis, eventually. Numerous implications connect impaired UPR signalling to
aberrant metabolic states and diseases [13,30,31].
Major metabolic abnormalities of altered UPR signalling are diabetes type I and II,
hepatosteatosis and impaired fatty acid metabolism [17,32]. Primarily, this is accounted
to the fact that the three UPR branches not only induce transcriptional programs
explicitly directed to the elimination of ER stress but simultaneously drive expression of
important metabolic regulators. Atf4 and sXbp1 are reported to control the expression
of genes involved in cholesterol and triacylglycerol metabolism [33,34]. Although Ire1α
full-knockout mice are embryonically lethal [35], hepatocyte-specific Ire1α ablation
leads to severe steatosis [36], which is consistent with the sXbp1 phenotype. Similar
phenotypes are also observable for impairments in the Atf6α branch. Atf6α-knockout
mice display fatty liver development and dysregulated expression of several lipid
metabolism master regulators after challenge with the ER stressor tunicamycin (Tm)
[15]. Furthermore, Atf6α-knockout mice were found to be glucose intolerant and
to develop liver steatosis after challenge with a high-fat diet (HFD) [37], and it was
suggested that Atf6α impedes hepatosteatosis by enhancing fatty acid β-oxidation via
regulation of peroxisome proliferator-activated receptor α (Pparα) gene expression
[38].
Other diseases associated with impaired UPR involve the innate immune system and
bone growth. sXbp1 was reported to be an important transcription factor for plasma
B cell differentiation [39] and the development and viability of dendritic cells [40].
Furthermore, it was shown that chondrocyte differentiation is inhibited in conditions of
unresolved ER stress, which leads to Schmid metaphyseal chondrodysplasia (MCDS),
a pathological condition characterised by dwarfism due to arrested or aberrant bone
growth [41,42].
7
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1.6 Glucose & Lipid metabolism and non-alcoholic fatty
liver disease
The food that we eat contains, besides other molecules, carbohydrates and lipids. Once
the food is digested, carbohydrates and lipids enter into the bloodstream inducing the
secretion of insulin by the pancreas. The signalling molecule insulin promotes the
uptake of glucose into cells and therefore is crucial for controlling the blood glucose
level. The other key player is glucagon, which stimulates the release of glucose into
the blood in conditions of starvation. The liver is the most sensitive organ to glucagon. It
is the primary site of glycogen storage due to its capability of trapping large amounts of
glucose and converting it to glycogen. These reserves can be mobilised rapidly through
conversion to glucose in states of low blood sugar levels.
Glucose is used for adenosine triphosphate (ATP) synthesis via the glycolysis pathway,
where glucose is converted to pyruvate, which then is converted to acetyl-coenzyme A
(CoA) to be completely oxidised in the citric acid cycle (CAC) (Figure 1.3).
Dietary lipids are transported in the bloodstream by lipoprotein vesicles. The contained
lipids are either absorbed by the liver, transported to adipose tissue for storage or to
the muscles, where lipids are oxidised for energy production. In adipocytes, lipids
are stored as triacylglycerides (TAGs). One TAG molecule is composed of one
glycerol and three fatty acids (acyls). When liver glycogen stores are deprived, TAG
stores from adipose tissue are mobilised via lipolysis and secreted to the bloodstream
as glycerol and free fatty acid (FFA) to serve as energy source for other organs.
Glycerols are taken up by the liver and converted to pyruvate via glycolysis or to
glucose via gluconeogenesis. FFAs can be taken up by organs and activated by
linking the fatty acid to CoA to produce acyl-CoA, which then can be degraded by
β-oxidation. Each round of β-oxidation generates one acetyl-CoA, which can enter the
CAC to generate ATP. However, acetyl-CoA can only enter the CAC after condensation
with oxaloacetate, which is a glucose metabolite produced during glycolysis. When
glucose levels are low, e.g. during starvation or in untreated diabetes, lipolysis
increases, FFAs are released and β-oxidation predominates for ATP synthesis. Severe
hypoglycemia results in the production of excess acetyl-CoA in the liver, which exceeds
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Figure 1.3: Overwiev of fatty acid metabolism. Lipolysis of TAGs in adipocytes results in the
release of glycerol and FFAs into the bloodstream. These are taken up by the liver. Glycerols are
either converted to pyruvate, which enters the CAC in the form of acetyl CoA, or to glucose and
secreted into the bloodstream for usage by extrahepatic cells. FFAs are oxidized producing
acetyl CoAs, which are used for ATP synthesis in the CAC. Excess acetyl CoA are either
converted to ketone bodies for usage as fuel source by extrahepatic tissues or can serve as
fundamental building blocks in cholesterol synthesis. Figure modified form ”Biochemistry” by
Stryer et al. [43].
the capacity to be oxidised in the CAC. This is due to the liver consumption of
oxaloacetate for gluconeogenesis to maintain constant blood glucose levels, thereby
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depriving the requiredmolecule for further acetyl-CoAdegradation. In this condition, the
liver converts acetyl-CoA to acetoacetate or β-hydroxybutyrate, which are collectively
termed ketone bodies. These ketone bodies are water soluble and released by the
liver into the blood. Ketone bodies diffuse through membranes and can be utilised
by extrahepatic organs as a fuel source, whereas the liver cannot use them for ATP
synthesis because it lacks an enzyme to activate ketone bodies.
Acetyl-CoAplays a further important role in the synthesis of cholesterol because it is the
building blocks of cholesterols. Cholesterols are esterified for storage or incorporated
into the plasma membrane in its unesterified form.
Non-alcoholic induced fatty liver disease (NAFLD) is characterised by the accumulation
of a significant amount of fatty acids, mostly TAGs, in hepatocytes and can be caused
by multiple factors. Nowadays, the leading causes of NAFLD are obesity and diabetes
type II. The pathogenesis of NAFLD involves a broad range of dysregulation in glucose
and lipid metabolism and, if untreated, NAFLD can progress to steatohepatitis, fibrosis
and cirrhosis [44,45]. Creld2 was observed to be upregulated in NAFLD induced mice
by feeding of an HFD [46]. Additionally, epigenome-wide association studies (EWAS)
in obese people found that CpG islands in the CRELD2 locus are methylated. Thus
CRELD2 transcription is inhibited [47, 48], suggesting a potential role of CRELD2 in
lipid metabolism.
Initial phenotypic analyses of the Creld2 full-knockout-mouse revealed that 1-year-old
Creld2-/- mice develop NAFLD, visible as excessive staining intensities in histological
oil-red-O stainings, which stain lipids in red (Figure 1.4). Furthermore, mice livers
revealed aberrant expression of genes important for glucose and fatty acid metabolism.
1.7 Bone structure, growth and remodelling
The body’s skeleton is composed of bones, a solid yet very dynamic type of connective
tissue that enables locomotion, which serves as a protection for internal organs and is
the major site of hematopoiesis. Bones come with distinct shapes and sizes depending
on their specific function in the body. However, besides this variety of different bones,
there are only two ways of bone formation resulting in the same bone tissue.
Flat bones are formed through intramembranous ossification, while long bones
10
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Figure 1.4: Histological analysis of Creld2KO liver sections. One year old Creld2KO
animals suffer from liver steatosis, which is visualised by a hematoxylin/eosin (HE) staining.
Cells in the area around the vessel harbor vesicles that were identified as lipid droplets using
an Oil-red-O staining. Figure and figure caption reprinted from Mass, 2013 [2].
are formed via endochondral ossification. The main difference between these
two ways of bone formation is that in intramembranous ossification bone is
formed directly from mesenchymal connective tissue, whereas during endochondral
ossification, mesenchymal stem cells (MSCs) first differentiate into chondrocytes,
which then provide the necessary ossification precursor cells for long bone formation.
Thus, endochondral bone formation involves the continuous supply of cartilage by
chondrocytes, which is replaced by bone tissue, afterwards. The continuous cartilage
supplies enable the bone to grow in length.
Long bones can be separated into three zones. The epiphysis, metaphysis and
diaphysis. The epiphysis is located at each end of the long bone and consists of
trabecular or spongy bone, a bone structure characterised by its porous appearance.
The metaphysis is a narrow bone region located between the epiphysis and the
11
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diaphysis and harbours the epiphyseal growth plate, which is responsible for
longitudinal bone growth. The diaphysis is the midsection of a long bone and makes up
the largest portion. It is a hollow shaft, called medullary cavity, which is surrounded
by cortical or compact bone. The medullary cavity is innervated by blood vessels,
which carry osteogenic cells. The medullary cavity is the storage and synthesis site
for bone-marrow (Figure 1.5a).
The crucial part for bone growth in the metaphysis is the epiphyseal growth plate
comprising a set of proliferating chondrocytes, which are responsible for longitudinal
bone growth (Figure 1.5b). The growth plate is divided into four zones. Adjacent
to the epiphysis is the reverse zone, where quiescent chondrocytes are situated
within a cartilage matrix. In the direction of the diaphysis, this layer is followed
by the proliferative zone, which consists of strongly proliferative chondrocytes.
Chondrocytes produced by mitotic proliferation are displaced toward the diaphysis
and are constituents of the third layer, the maturation and hypertrophy zone. Here,
chondrocytes become larger as they mature and travel closer and closer to the
diaphysis. The zone of calcification is following the maturation layer and is the layer
where chondrocytes go into apoptosis because the cartilage matrix starts to calcify. As
the ossification layer is pushed closer to the diaphysis due to the dividing chondrocytes
in the proliferative zone, the calcified chondrocyte tissue is innervated by blood vessels
and osteoblasts. Osteoblasts are bone-producing cells, which replace the calcified
matrix by bone tissue. Eventually, proliferation of chondrocytes in the epiphyseal growth
plate stops and the growth plate is replaced by trabecular bone tissue.
Trabecular bone in the epiphysis is constantly remodelled due to an interplay between
bone forming osteoblasts and bone reabsorbing osteoclasts. The process of bone
formation and resorption is tightly regulated. In principle, osteoclasts are activated
by osteoblasts, which secrete signalling molecules that induce osteoclastic bone
resorption. Vice versa, osteoclasts activate osteoblasts during the process of bone
resorption to ensure subsequent bone renewal (Figure 1.5c). Aberrant osteoblast or
osteoclast function leads to pathologies, such as osteoporosis, which is the reduction
of bone mass, or osteopetrosis, the increase of bone mass (Figure 1.5d) [49].
Creld2 analyses in models of multiple epiphyseal dysplasia (MED) suggest that
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Creld2 interacts with non-native cartilage extracellular matrix (ECM) proteins in a
substrate-specific manner. It was further proposed that Creld2 exhibits protein disulfide
isomerase (PDI)-activity and thereby assists in the folding of these ECM protiens
[50]. Furthermore, Creld2 was suggested to augment bone formation by enhancing
expression of bone morphogenic protein 9 (BMP9) downstream targets, which are
important for osteogenic differentiation of MSCs [51].
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Figure 1.5: Long bone growth and structure. (a) Separation of long bones into the epiphysis,
metaphysis and diaphysis. (b) Detailed depiction of the epiphyseal growth plate. Left:
Growth plate zone classification. Right: Changes induced in differentiating chondrocytes in
the respective growth plate zones. (c) Regulation of bone remodelling by osteoblasts and
osteoclasts. Reciprocal activation of osteoblasts and osteoclasts by released factors during
bone formation and resorption, respectively. (d) Defects in bone remodelling cells can results
in increased bone density (Osteopetrosis, left) or reduced bone mass and bone (Osteoporosis,
right) compared to normal bone structure (center). Figures in (a), (c) and (d) were adapted
and modified from Smart Servier [52]. Figure in (b) was adapted and modified from Schatz,
2016 [53].
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1.8 Aim of the thesis
Although Creld2 was identified nearly 20 years ago, only little is known about its
physiological or molecular function. In this work, the role of Creld2 under steady state
as well as stress conditions was investigated in vivo and in vitro utilising a Creld2-/-
mouse model and Creld2-/- mouse embryonic fibroblasts (MEFs), respectively.
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2.1 Equipment
Table 2.1: Equipment
Equipment Company/ Model
Agarose gel electrophoresis chamber Thermo scientific Owl Electrophoresis
Systems B2
Autoclave H+P Varioklav Dampfsterilisator EP-2
Bacteria incubator Innova 44 NEW Brunswick scientific
Balances Sartorius BL 150; Sartorius B211 D
Binocular Zeiss Stemi 2000
Centrifuges 5415R/5424 Eppendorf; Avanti J-26
XP Beckman Coulter; Biofuge primo
R Heraeus; Rotina 420 R
Cryostat Leica
Electro pipette Accu Jet
Electroporator Biorad Gene Pulser Xcell
Embedding carrousel Leica TP 1020
Gel documentation Benda Biostep Dark Hood DH-40/50
Incubators/shaker Heiz Thermo Mixer MHR13 HLC
(Memmert); Innova 44 NEW
Brunswick scientific
Microplate reader Tecan Infinite 200 Pro
Microwave Panasonic
Photometer Nano Drop 2000 PeqLab;
Power supply Pover Pac HC BioRad
Radiopraphic cassettes Radiographic Products
RealTime PCR thermo cycler CFX96 BioRad
Thermo cycler C1000 Thermal Cycler BioRad
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Table 2.1: continued from previous page
Equipment Company/ Model
Turbo-blotter BioRad Tans-Blot Turbo Transfer
System
Vortexer Vortex Genie2
Water bath Jubalo SW22
Western blotting equipment Biorad
X-ray film developer machine Curix 60 AGFA
2.2 Consumables
Table 2.2: Consumables
Consumables Company
1.5/ 2 ml reaction tubes Eppendorf
Cover slips VWR
Electroporation cuvettes 0.4 cm Biorad
Embedding cassettes Simport
Immobilon PVDF membrane Merck
Microscope slides VWR
PCR reaction tubes Sarstedt
Plastic wares Greiner
Protein purification columns BioRad Micro Bio-Spin Columns 0.8
ml
PVDF membrane Millipore Immobilon-P Transfer
membranes 0.45µm
Superfrost Plus adhesive microscope
slides
Thermo scientific
Syrringes BBraun Injekt-F
Tissue-Tek Sakura
TLC plates Millipore HPTLC Silica gel 60
X-ray films Fuji Medical X-Ray Film Super RX
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2.3 Chemicals & solutions
Table 2.3: Chemicals
Chemical Company
Crystal violet Roth
Eosin VWR
Fetal calf serum PAN-Biotech
Hematoxylin VWR
Oil-red O Sigma
Paraffin Medim-Plast
Penicillin/Streptomycin Invitrogen
Thapsigargin Sigma
Tissue-Tek Sakura
Trypsin Sigma
Tunicamycin Sigma
2.4 Standards and Kits
Table 2.4: Standards and Kits
Name Company
2-Log DNA ladder, 1 kb DNA ladder NEB
Complete Protease Inhibitor Cocktail tablet Roche
DAPI-Fluoromount G Biozol
ECL Western Blotting Substrate Pierce
FLAG M2 Affinity Gel Sigma-Aldrich
Flag peptide Sigma-Aldrich
Fluorescence microscope ZeissAxioCamMRm;
Olympus SZX 12
iQ TM SYBR Green Supermix BioRad
Masson-Goldner trichrome staining kit Merck
Microtome Leica RM2255
NBT/BCIP stock solution Roche
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Table 2.4: continued from previous page
Name Company
Nova Red Vector Laboratories
Nucleic Acid & Protein Purification, NucleoBond, PC
100
Macherey & Nagel
Nucleic Acid & Protein Purification, NucleoSpin, RNAII Macherey & Nagel
NucleoSpin Gel and PCR Clean-Up Macherey & Nagel
NucleoSpin RNA XS Macherey & Nagel
NucleoSpin RNA/Protein Macherey & Nagel
PCR Nucleotide Mix Roche
Pierce BCA protein Assay kit Thermo scientific
Precision plus Protein All Blue Standards BioRad
QuantiTect, Reverse Transcription Kit Qiagen
Ready-to-use System for fast Purification of Nucleic
Acids, NucleoSpin, Extract II
Macherey & Nagel
Strep-Tactin Sepharose IBA
Tissue homogenizer Precellys Peqlab
2.5 Bacterial strains
Table 2.5: Bacterial strains
Strain Genotype Origin
DH5α
F- ϕ80lacZ∆M15
∆(lacZYA-argF)U169 deoR recA1
endA1 hsdR17(rK-, mK+) supE44
gyrA96 (Nalr) thi-1 relA1
Stratagene
2.6 Buffers & solutions
Table 2.6: Buffers
Buffer/Solution Recipe
Agarose 1–2.5% agarose (w/v) in TAE
Ammonium persulfate (APS) 10% APS
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Table 2.6: continued from previous page
Buffer/Solution Recipe
Ampicillin (−20 ◦C) 1000x stock 50mg/ml Ampicillin
Blocking solution 5% skim milk powder in TBST
Decalcifying solution 14% EDTA, 3% Ammonium
Hydroxyde, pH 7.1 in ddH2O
Fixation solution freshly prepared 4% MeOH-free
Formaldehyde (PFA) in DPBS
Flag elution buffer 200 µg/ml Flag peptide in TBS (1x)
Flag peptide stock (−80 ◦C) 5mg/ml Flag peptide in TBS (1x)
Glycerine jelly mounting medium 10g Gelatin, 60ml ddH2O, 70ml
Glycerol, 0.25g Phenol
Laemmli loading buffer (1x) 2% SDS, 2 µM Dithoithreitol (DTT),
5% (v/v) Glycerol, 50 µM Tris-HCL
(pH 6.8), 0.01% (w/v) Bromophenol
blue
Laird buffer 0.1M Tris (pH 8.0), 0.2% SDS, 0.2M
NaCl, 5 µM EDTA
Lysozyme (−20 ◦C) 10mg/ml in TE-buffer
Oil-red O stock solution 0.5% Oil-red O in isopropanol
Oil-red O working solution 30ml Oil-red O stock solution in 20ml
ddH2O
PBS (20x) 4 g KCl, 160 g NaCl, 28.6g Na2HPO4,
4 g KH2PO4
PBST 0.1% Tween20 in PBS (1x)
Proteinase K stock (−20 ◦C) 20mg/ml in DEPC
SDS 10% SDS
SDS-PAGE running buffer (10x) 250µM Tris-HCL, 1.92M Glycine, 1%
SDS
TAE buffer 40 µM Tris-Acetate (ph 8.0), 1 µM
EDTA
19
2 Materials
Table 2.6: continued from previous page
Buffer/Solution Recipe
TAP-elution buffer 50 µM Desthiobiotin in TBS (1x)
TAP-lysis buffer For 10ml: 1ml TBS (10x), 200µl
Complete Protease Inhibitor Cocktail
(50x), 100 µl Phosphatase Inhibitor
Cocktail (PIC) I and II, 50 µl NP40,
8.55ml H2O
TAP-wash buffer For 10ml: 1ml TBS (10x), 100 µl PIC
I and II, 10 µl NP40, 8.79ml H2O
TBS (10x) 5.6g Tris-base, 24 g Tris-HCl, 87.8g
NaCl in 1000ml of H2O, pH 7.5
TBST 0.1% Tween20 in TBS (1x)
TE buffer 10 µMTris-HCL (pH 7.5), 0.15MNaCl,
0.05% Tween20
Transfer buffer 30.3g Tris, 144.2g Glycine in 1 l H2O
2.7 Media
Table 2.7: Media for bacterial culture
Medium Recipe
LB-medium 10g NaCl, 10 g tryptophan, 5 g yeast extract, add
1 l of H2O (pH 7.0)
LB-ampicillin medium LB-medium with 50µg/ml ampicillin
LB-kanamycin medium LB-medium with 25µg/ml kanamycin
LB-ampicillin agar LB-medium with 20 g agar and 50µg/ml
ampicillin
LB-kanamycin agar LB-medium with 20 g agar and 25µg/ml
kanamycin
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Table 2.8: Media for cell culture
Cell line Recipe
Hek293, MEFs 10% Fetal calf serum, 1% Penicillin/Streptomycin in
DMEM
2.8 Antibodies
Table 2.9: Antibodies
Antibody Conjugate Species
Method
(dilution)
Company
Akt – rab WB
(1:1000)
Cell Signaling
β-Actin (AC-15) – mouse WB
(1:5000)
Novus Biologicals
CD117 (c-KIT)
(2B8)
PE or APC
Cy7
FACS
(1:100)
Biolegend
CD11b (M1/70) PE or PE
Cy7
FACS
(1:100)
BD Pharmingen
CD150
(TC15-12F12.2)
PE Cy7 FACS
(1:100)
Biolegend
CD16/32 (2.4G2) Uncoupled FACS
(1:100)
BD Pharmingen
CD19 (1D3) BV711 FACS
(1:100)
BD Pharmingen
CD3 (145-2C11) PE FACS
(1:100)
Biolegend
CD335 (NKp46)
(29A1.4)
PE FACS
(1:100)
ebioscience
CD45 (30-F100) AF780 FACS
(1:100)
ebioscience
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Table 2.9: continued from previous page
Antibody Conjugate Species
Method
(dilution)
Company
CD48 (HM48-1) APC FACS
(1:100)
Biolegend
Chop (L63F7) – mou WB
(1:500)
Cell Signaling
Creld2 (G-17) – rab WB
(1:750)
Santa Cruz
eIF2 (9722) – rab WB
(1:1000)
Cell Signaling
F4/80 (2M8) eF450 or
APC or
BV605
FACS
(1:100)
eBioscience
Flag M2 – mouse WB
(1:500)
Sigma
Gadd34 (H-193) – rab WB
(1:400)
Santa Cruz
GFP – rab WB
(1:300)
Santa Cruz
Gr1 (RB6-8C5) e450 or FITC
or PE
FACS
(1:100)
BD Pharmingen
Grp78 – rab WB
(1:2000)
StressMarq
Biosciences
Hoechst 33258 – FACS
(1 µg/ml)
Invitrogen
Ly-76 (Ter119) BV650 or
PercP
FACS
(1:100)
BD Pharmingen
Mouse HRP Donkey WB
(1:15000)
Santa Cruz
22
2 Materials
Table 2.9: continued from previous page
Antibody Conjugate Species
Method
(dilution)
Company
Perk (C33E10) – rab WB
(1:750)
Cell Signaling
Phospho-Akt
(S473) (D9E)
– rab WB
(1:750)
Cell Signaling
Phospho-eIF2
(Ser51) (D9G8)
– rab WB
(1:500)
Cell Signaling
Phospho-Perk
(T980) (16F8)
– rab WB
(1:500)
Cell Signaling
Rabbit HRP Donkey WB
(1:15000)
Santa Cruz
Sca1 (D7) BV421 FACS
(1:100)
BD Pharmingen
Tim4 (RMT4-54) AF647 FACS
(1:100)
Biolegend
2.9 Plasmids
Table 2.10: Plasmids used
Plasmid Source
pcDNA3.1Zeo+ AG Hoch (T. Krsmanovic)
FS-C2 in pcDNA3.1Zeo+ P. Kern
C2-SF in pcDNA3.1Zeo+ P. Kern
SF-mock in pcDNA3.1Zeo+ P. Kern
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2.10 Primer & gene blocks
2.10.1 Genotyping primer
Table 2.11: Primer for genotyping
Primer name Primer sequence (5’–3’)
Creld2 wt genotype fw CCTGAGCTGTCCTTAGAAAGTTGCTAG
Creld2 ko genotype fw GCCCGACAACCACTACCTGAGC
Creld2 genotype rev GGGGTTCATGTCCATGGGCCAC
2.10.2 Cloning primer
Table 2.12: Primer for cloning
Primer name Primer sequence (5’–3’)
NheI-Kozak-mC2-SF-tag fw CTAGCTAGCGCCACCATGCACCTGCTGCTTGCA
Creld2-KpnI TATGGTACCTCACAAATCCTCACGGGAGGG
KpnI-Flag rev TAGGGTACCTCACTTGTCGTCGTC
NheI-SF-tag fw CTAGCTAGCATGGGTGGAGGTTCTGGA
KpnI-SF-tag rev GGAGCTCTGGATGGTACCTCACTTGTC
2.10.3 qRT-PCR primer
Table 2.13: Primer for quantitative real time PCR
Gene Forward primer (5’–3’) Reverse primer (5’–3’)
Acox1 GCCTTTGGACCTTCACTTGG GATGAGTTCCATGACCCATCT
CT
Apcs TGTGGGACTATGTGCTGACC ATCTCAATCCCAGACACGGG
ApoB100 GGAATCCCCCAGATGGTTGT ACTCCAGACGAGGACACTTG
Apoc2 GCTTTGTTGGCCAGGACTTT TGTCTGGGACCTGAATGTAGT
G
Atf6 AATGGGGCCCTCCTCAGGGG GGGCCTGTGCTAGCGCACAA
Chop TCACCTCCTGTCTGTCTCTCC TACCCTCAGTCCCCTCCTC
Creld2 GGCTACACCAAGGAGAGTGG GGACACACGCACACGAAG
Derl1 GAAACCTTGTCGGCCATCTT GGTAGCCAGCGGTACAAAAA
Derl2 TTCTAAACTTCCAGGCCCCC CTGCAATACCCAAAAGGTCCA
Derl3 CTTCGTGTTCCGCTACTGC CCAGGAATCCCAGCAGAGT
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Table 2.13: continued from previous page
Gene Forward primer (5’–3’) Reverse primer (5’–3’)
Dgat1 TCAAGGCCAAAGCTGTCTCTA AGGTCAGGTTGTCTGGATAG
C
Dgat2 TATCCTTCCTGGTGCTAGGAG
T
CTTTCTTGGGCGTGTTCCAG
Dr5 AAAAGAGGCTGTGAACGGGA GCTAGATGTCTGTCGGTCCA
Edem1 GGTCTTCGAAGCTACGATAAG
G
GGGCTGTTTGGAATCAGTTAT
TA
Edem2 ACTACAGGGAGCGAGTCAAG GTCCAGGGCATCAATTAGCG
Edem3 GATGGGAAGGACACAGACGA TCCATTTCGGGATCTCGGTC
Erk1 GATCCGACAGATGAGCCAGT ATCCAAAAGGACAGGGGTGT
Erk2 CCCAAGTGATGAGCCCATTG ACACCGACATCTGAACTCGT
Fit2 GCAACGTCCTCAACGTGTATT AGGTGGTAGTTGGTAAGGGC
Fsp27 TCATGAGGTGTGCGAGAGAG GCATTCCCTAAGGTCCCTCC
Gadd34 ACGATCGCTTTTGGCAAC GACATGCTGGGGTCTTGG
GFP TGAGCAAAGACCCCAACGA CGTCCATGCCGAGAGTGAT
Glut2 GGGACTTGTGCTGCTGGATA AATTGCAGACCCAGTTGCTG
Glut4 CCGAAAGAGTCTAAAGCGCC GCTCTCTCTCCAACTTCCGT
Grp78 CGACAAGCAACCAAAGATG CCAGGTCAAACACAAGGATG
Grp94 GCGGCGGATTAAGGAAGATG TACGCCTTGGTGTCTGGTAG
Hprt TCCCAGCGTCGTGATTAGCG
ATGA
AATGTGATGGCCTCCCATCTC
CTTCATGACAT
Il1b AGCTTCCTTGTGCAAGTGTC TCTTTTGGGGTCCGTCAACT
Il6 GTGGAAATGAGAAAAGAGTTG
TGC
GTTTTCTGCAAGTGCATCATC
G
Ire1a TGCTGAAACACCCCTTCTTC CTCCCGCCTCTCTCCAAC
Lsr TTGGCAGGACCTCAGAAGC CCACAAAGAGCCAATCTTCCA
A
Perk CGGGACAAGTAGGGACCAAG GGTGCTGAATGGGTAGAGGA
G
Pgc1a GTGTGCTGTGTGTCAGAGTG ACCAGAGCAGCACACTCTATG
Pgc1b AACTTCAGACGTGAGAGCAG
A
TATACCACACGGCCTTCACC
Plin2 CGGTTGCCAATACCTATGCC CACTGGCAACAATCTCGGAC
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Table 2.13: continued from previous page
Gene Forward primer (5’–3’) Reverse primer (5’–3’)
Ppara CATTTGGGCGTATCTCACCG AACTTCAACTTGGCTCTCCTC
T
Ppia GCGTCTCCTTCGAGCTGTT AAGTCACCACCCTGGCA
Saa3 AAGTCATCAGCGATGCCAGA ACTGGTCAGCTCTTGAGTCC
sXbp1 CTGAGTCCGCAGCAGGT CCAACTTGTCCAGAATGCCC
Tnf GCCCACGTCGTAGCAAAC GGAGTAGACAAGGTACAACC
CA
2.10.4 Gene blocks
Table 2.14: Gene blocks used for cloning
Gene block Sequence (5’–3’)
N-term FS-C2
CTAGCTAGCGCCACCATGCACCTGCTGCTTGCAGCCGC
GTTCGGGCTGCTGCTGCTGCTGCCGCCGCCCGGGGCC
GTAGCCGACTACAAGGACGACGACGACAAGGGCGCCA
GCGGCGAGTGGAGCCACCCCCAGTTCGAGAAGGGAGG
TGGATCAGGCGGTGGATCTGGTGGAGGTTCCTGGTCG
CATCCACAATTTGAAAAGGGTGGAGGTTCTGGAGGTGG
TTCAGGAGGAGGTAGTTCCCGGAAGCCGACGATGTGCC
AGAGATGCCGGACGCTGGTGGACAAGTTCAACCAGGG
GATGGCCAACACGGCCAGGAAGAATTTCGGTGGCGGC
AACACGGCGTGGGAAGAGAAGACGCTGTCTAAGTACGA
ATTCAGTGAGATCCGGCTTCTGGAGATCATGGAGGGTC
TG
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Table 2.14: continued from previous page
Gene block Sequence (5’–3’)
C-term C2-SF
GAAAAAGCCTGTAAGAGGAAAAACGAAAACTGCTACAA
TGTTCCGGGGAGCTTCGTGTGCGTGTGTCCGGAAGGCT
TTGAGGAGACAGAAGACGCTTGTGTGCAGACAGCAGAA
GGCAAAGTCACAGAGGAAAACCCCACACAGCCACCCTC
CCGTGAGGATTTGGGTGGAGGTTCTGGAGGTGGTTCAG
GAGGAGGTAGTTGGAGCCACCCCCAGTTCGAGAAGGG
AGGTGGATCAGGCGGTGGATCTGGTGGAGGTTCCTGG
TCGCATCCACAATTTGAAAAGGGCGCCAGCGGCGAGGA
CTACAAGGACGACGACGACAAGTGAGGTACCGAGCTCG
GATCCACTAGTCCAGTGTGGTGGGTCTAGAGGGCCC
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3.1 Histological stainings
3.1.1 Preparation of organ samples for histological analysis
For histological staining, organs were fixed in fixation solution for 24 h at 4 ◦C.
Subsequently, fixed organ samples were embedded either in Paraffin or processed for
cryo-sectioning. Embedded tissue samples were sectioned at 10 µm depth.
3.1.2 Preparation of bone samples for histological analysis
Whole bones were fixed in fixation solution for 72 h at 4 ◦C with constant agitation.
After fixation, bones were washed twice in PBS for 10min. Subsequently, bones were
decalcified in decalcifying solution for 96 h at 4 ◦C with constant agitation. Decalcified
bones were washed twice in PBS for 10min prior to paraffin or cryo embedding.
3.1.3 Paraffin embedding
Fixed organ samples were dehydrated in increasing ethanol concentration series (70%,
70%, 80%, 80%, 90%, 96%, 100%, 100%) followed by incubating twice in xylol and
twice in wax. Tissue samples were incubated for 1 h in each step.
3.1.4 Cryo embedding
Directly after fixation, tissue samples were incubated in 30% sucrose solution at 4 ◦C
for 24 h. Afterwards, tissue samples were embedded in Tissue-Tek freezing resin and
stored at −20 ◦C for short-term or −80 ◦C for long-term storage.
3.1.5 Hematoxilin & Eosin staining
Prior to staining of tissue sections, samples were deparaffinized in xylol rehydrated in
descending ethanol series (100%, 100%, 96%, 90%, 80%, 70%, 60%). Afterwards,
samples were stained in Hematoxylin solution for 3min and rinsed in running tap water
for 3min, followed by staining in Eosin solution for 3min with subsequent rinsing under
tap water for 30 sec. Stained sections were dehydrated in increasing ethanol series (as
mentioned above), cleared in xylol twice and mounted in Entellan.
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3.1.6 Masson-Goldner Trichrome staining
Prior to staining of tissue sections, samples were deparaffinized in xylol rehydrated
in descending ethanol series (twice in 100%, 96%, 90%, 80%, 70%, 60%).
Subsequently, sections were stained in Hematoxylin for 5min and rinsed for another
5min under running tap water. Afterwards, samples were rinsed in 1% acetic acid for
30 sec and incubated in Azophloxine solution for 10min. Sections were rinsed again in
1% acetic acid for 30 sec, stained in orange G solution for 1min and rinsed another time
in 1% acetic acid for 30 sec followed by incubation in light green SF solution for 2min.
Samples were rinsed in 1% acetic acid for 30 sec, dehydrated in ascending ethanol
series, cleared twice in xylol and mounted in Entellan.
3.1.7 Oil-red O staining
Cryo-embedded tissue sections were let to dry on microscope slides, fixed with fixation
solution and washed under running tap water for 5min. Sections were rinsed in 60%
isopropanol and stained with freshly prepared Oil-red Oworking solution for 15min prior
to rinsing with 60% isopropanol. Subsequently, samples were stained with hematoxylin
by dipping the sections 5 times into the solution, rinsed with ddH2O and mounted in
glycerine jelly mounting medium.
3.2 Isolation of RNA
RNAwas isolated either using the Nucleospin RNA II kit according to themanufacturer’s
protocol or, in case of limited sample amount, by cytoplasmic extraction of RNA.
For the cytoplasmic extraction of RNA tissue or cell pellet was homogenized in 200
200µl cytoplasmic RNA lysis buffer and incubated on ice for 10min to lyse cells.
Afterwards, the lysate was centrifuged for 10min at 4 ◦C to sediment nuclei. The
supernatant was recovered, SDS and proteinase K were added to a final concentration
of 1% and 0.5mg/ml, respectively followed by digestion at 37 ◦C for 3 h. After
digestion of proteins, RNAs were extracted twice by adding 150µl Phenol/Chloroform
(1:1), centrifugation of the mixture for 10min at RT and the upper aqueous phase
was recovered. Subsequently, the harvested lysates were washed twice with 150µl
chloroform alone to remove potential phenol contaminations. The aqueous phase was
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harvested and 15µl of 3MNaOAc (pH 4.8–5.5) and RNAwas precipitatedO/N at−80 ◦C
after addition of 500 µl absolute EtOH. Afterwards, the mixture was centrifuged for
15min at 4 ◦C, the supernatant was discarded and the RNA pellet was dried shortly
to eliminate EtOH contamination. Pure RNA was resuspended in 20–40µl H2O.
3.3 Reverse transcription of RNA into cDNA
cDNA was synthesized by reverse transcription of isolated RNA using Qiagen
QuantiTect reverse transcription kit including rDNaseI treatment according to the
manufacturer’s protocol. Up to 500 ng of total RNA was used in a 10 μl reaction and
filled up to 50 μl with aqua bidest after cDNA synthesis.
3.4 PCR techniques
Primer stock concentration for PCR was 100pmol/µl unless otherwise stated.
3.4.1 Genotyping PCR
Table 3.1: Genotyping PCR Protocol
Component Volume / 20 µl reaction
H2O 14.7µl
5x GoTaq reaction buffer 4 µl
DNTPs 0.4µl
Forward primer 1 0.1µl
Forward primer 2 0.1µl
Reverse primer 0.1µl
DNA template 0.5µl
GoTaq DNA polymerase (5U/µl) 0.1µl
Table 3.2: Genotyping PCR program
Step Temperature (◦C) Time Number of cycles
Initial denaturation 95 3min 1
Denaturation 95 20 sec
Annealing 57 15 sec 30
Extension 72 15 sec
Final extension 72 5min 1
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Table 3.3: PCR Protocol Creld2 cDNA amplification
Component Volume / 20 µl reaction
5x Phusion buffer 4 µl
DNTPs 0.4µl
NheI-Kozak-mC2-SF-tag fw 0.1µl
Celd2-KpnI rev 0.1µl
Template DNA 1µl
Phusion polymerase 0.2µl
ddH2O 14.2µl
Table 3.4: Creld2 cDNA amplification PCR program
Step Temperature (◦C) Time Number of cycles
Initial denaturation 98 30 sec 1
Denaturation 98 10 sec
Annealing 65 15 sec 5
Extension 72 30 sec
Denaturation 98 10 sec
Annealing 72 15 sec 25
Extension 72 30 sec
Final extension 72 5min 1
3.4.2 Cloning PCR
3.4.2.1 Cloning of N-terminally tagged Creld2
The N-term FS-C2 gene block (gBlock) was cut out of the Topo vecotor with NheI-HF
and EcoRI-HF and purified from an agarose gel. Creld2 cDNA was amplified and
digested with EcoRI-HF and KpnI-HF and the 3’ fragment was purified from an
agarose gel. Purified gBlock and 3’ PCR product were ligated and subcloned into the
pcDNA3.1Zeo+ vector for transfection of cells.
3.4.2.2 Cloning of C-terminally tagged Creld2
Subcloned Creld2 cDNA in a pcDNA3.1Zeo+ vector was digested with EcoNI and XbaI
and the vector containing the 5’ Creld2 fragment was purified. The C-term C2-SF
gBlock was digested with EcoNI and XbaI and ligated with the pcDNA3.1Zeo+ vector
containing the 5’ Creld2 part.
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Table 3.5: PCR Protocol SF-mock tag amplification
Component Volume / 20 µl reaction
5x Phusion buffer 4 µl
DNTPs 0.4µl
NheI-SF-tag fw 0.1µl
KpnI-SF-tag rev 0.1µl
Template gBlock 1 µl
Phusion polymerase 0.2µl
ddH2O 14.2µl
Table 3.6: SF-mock tag amplification PCR program
Step Temperature (◦C) Time Number of cycles
Initial denaturation 98 30 sec 1
Denaturation 98 10 sec
Annealing 55 15 sec 5
Extension 72 10 sec
Denaturation 98 10 sec
Annealing 72 15 sec 30
Extension 72 10 sec
Final extension 72 5min 1
3.4.2.3 Cloning of the SF-mock vector
For generation of the SF-mock tag, the SF-tag was amplified from one of the used
gBlocks and subcloned into the pcDNA3.1Zeo+ vector.
3.4.3 qRT-PCR
qRT-PCR primer were designed either by using the Universal Probe Library (Roch
Applied Science) or by using Primer-Blast (NCBI). Primers were desalted and without
5’ or 3’ modifications from IDT and supplied lyophilized.
Table 3.7: qRT-PCR Protocol
Component Volume / 15 µl reaction
Template cDNA 0.75µl
Forward primer 0.375µl (5 pmol/µl)
Reverse primer 0.375µl (5 pmol/µl)
2x SYBR-Green Supermix 7.5µl
ddH2O 6µl
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3.4.4 Total lipid extraction in solution by Bligh & Dyer
Total lipids were extracted from mice livers. On ice, tissue samples were weighed,
cut into small pieces and transferred to Precellys tubes. Sample concentration was
adjusted to 50mg/ml with respect to the tissue’s wet weight and homogenized in a
Precellys tissue homogenizer until samples were free of intact tissue pieces. In case
of homogenization iterations samples were placed on ice for 2min. Subsequently,
0.8ml of the homogenate were transferred into a Pyrex glass tube and 3ml of 1:2 (v/v)
CHCl3:MeOH were added. Mixture was vortexed for 10 sec. Afterwards, 1ml of CHCl3
and 1ml of ddH2O were added consecutively. Mixtures were vortexed as mentioned
above after each addition and centrifuged at 1000 x g for 5min at RT. Following
centrifugation as much as possible of the bottom, solvent, phase was recovered with
a Pasteur pipette without contaminating it with the aqueous phase. Subsequently, the
same amount of recovered solvent phase of each sample was transferred to a new
Pyrex tube and solvents were evaporated under a steam of N2 gas. Finally, extracted
lipids were resuspended in 100µl of 1:1 (v/v) CHCl3:MeOH. The final concentration of
extract in respect to the wet weight of tissue per µl was calculated and lipid extracts
according to 1mg of tissue were subjected to thin layer chromatographical analysis.
3.5 Western blotting
Proteins separated by SDS-PAGE were transferred to a PVDF membrane. The
membrane was activated with methanol for 1min and equilibrated in transfer buffer.
SDS-PAGE gels and Whatman papers were equilibrated in transfer buffer and
assembled to a transfer sandwich. The membrane was oriented to the anode, whereas
the gel was oriented to the cathode. Proteins were blotted in the turbo-blotter using
standard protocol for mixed molecular weight protein transfer predefined by BioRad.
3.6 Antibody binding and ECL detection
After the transfer of proteins the membrane was blocked with 5% skim milk powder in
TBST for 30 min. The membrane was incubated with primary antibody in TBSTwith 5%
skim milk powder o/n at 4 ◦C. After incubation, the membrane was washed 3 times for
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5min in TBST to reduce unspecific binding and incubated with the secondary antibody
for 1 h. Membrane was washed 3 times for 5min and the ECL substrate was added
for the production of chemiluminescence. For the detection of luminescence signals
X-Ray film was used. X-ray films were developed in a Curix60 developer.
3.7 Cell culture
3.7.1 Isolation and culture of mouse embryonic fibroblasts
Pregnant mice were sacrificed and embryos (E12.5) were obtained. Heads of the
embryos were removed and used for genotyping. Heart and liver were removed
from the embryo bodies and embryos were incubated in (0.05%) trypsin-(0.48mmol)
EDTA solution for 30 min at 37 ◦C with shaking at 900 rpm. Subsequently, pre
warmed Dulbecco’s Modified Eagle Medium (DMEM; Invitrogen) supplemented with
10% fetal calf serum (FCS; Pan Biotech) and 1% Penicillin-streptomycin (10 000U/mL;
Thermo Scientific) was added to stop trypsin-EDTAactivity and the cell suspension was
centrifuged at 100 x g for 5min. After substitution of the supernatant with fresh DMEM,
MEF cells were resuspended and the cell suspension was transfered onto a culture dish
plate and incubated in DMEM at 37 ◦C in an incubator with a humidified atmosphere of
5% CO2. Cells were passaged at a confluence of 70% to 80%.
3.7.2 Induction of ER stress
ER stressors Tg and Tm were resuspended in Dimethyl sulfoxide(DMSO). For the
analysis of UPR pathways in Creld2+/+ and Creld2-/- MEFs during ER stress, 0.5× 106
MEF cells of passage 3 were seeded onto 6-well culture dishes one day prior to the
start of treatment. Control cells (designated as 0 h) were incubated in DMEM supplied
with FCS, appropriate antibiotics and the equivalent volume of DMSO as was used for
cells treated with Tg or Tm.
3.7.2.1 Induction of acute ER stress
Seeded cells were cultured in the presence of 1 µMTg for 1,2,4 or 8 h. Untreated
cells served as 0 h controls. After the respective treatment time, cells were harvested.
A small fraction of harvested cells was seeded out for analysis of cell viability. The
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remaining cells were subjected to gene expression and immunoblot analysis.
3.7.2.2 Induction of chronic ER stress
Chronic ER stress was induced in Creld2+/+ and Creld2-/- MEFs by treatment with
various concentrations of Tg for 48 h or Tm for up to 72 h. Medium and stressors were
refreshed daily. At the indicated time points, cells were either sampled for molecular
analysis or subjected to cell viability analysis.
3.7.2.3 Induction of transient ER stress
For induction of transient ER stress 0.5× 106 MEF cells were seeded into 6-well culture
plates the day before the experiment. The next day, ER stress in MEFs was induced
by Tm (2µg/mL) or Tg (1 µM) for 2 h. After the incubation with ER stressor the medium
was replaced by DMEM alone and cells were incubated for 4, 8, 28 and 46h. Control
cells were incubated without ER stressor in DMEM.
3.7.2.4 Cell viability assay
To analyze cell viability of Creld2+/+ and Creld2-/- during ER stress, MEFs were seeded
into 96-well plates as doublets one day prior to the start of treatment. The following day,
cells were incubated with either TM (25 ng/ml, 50 ng/ml or 100 ng/ml; Sigma-Aldrich)
or Tg (2.5nM, 5 nM or 10 nM; Sigma-Aldrich) in DMEM for 1 or 2 days. As control,
cells were incubated without Tm or Tg. At the indicated time points cells were fixed
with Histofix 4% (Roth) for 5min and stained with Crystal violet (0.05% in ddH2O; Roth)
for 30min. Stained cells were washed twice with tap water and air-dried. After drying
MeOH was added to solubilize the dye and staining intensity was measured with a
Fluostar Omega (BMG Labtech) plate reader at 590 nm.
3.7.2.5 Electroporation of cells
Prior to electroporation, adherent cells were trypsinized and washed twice with PBS and
cell concentration was adjusted to 5× 106–2× 107 cells/ml with Optimemmedium. For
electroporation 0.5ml of the cell suspension was transferred to a 4mm electroporation
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cuvette, mixed with 2.5µg DNAper 106 cells without introducing bubbles and incubated
for 15min. Directly before electroporation, the mixture was resuspended by gently
tapping the cuvette so that no bubbles were produced and cells were electroporated
at 250V, 950µF, ∞Ω in exponential mode. Immediately after electroporation, 1ml
of DMEM containing 10% FCS, without antibiotics, was added to the cell suspension
and cells were incubated in cell culture flasks for 24 h prior to changing the medium to
DMEM containing the proper antibiotics.
3.7.3 Tandem affinity purification
The protocol for tandem affinity purification (TAP) was adapted from Gloeckner et
al. [54]. Transiently over expressing HEK293 cells were cultured for 72 h post
electroporation for the initial analysis of Creld2 interaction partners. For extensive
investigation on Creld2 protein interactions TAP was performed with stably expressing
HEK293 cells. Buffers for TAP were prepared freshly on the same day of purification
Cells were trypsinized and incubated in 1ml/5× 107 cells of ice cold TAP-lysis buffer
for 20min on ice. The lysates were centrifuged for 10min at 10 000 xg at 4 ◦C and
the supernatants were recovered. Afterwards, cell lysates were incubated with 100µl
Strep-tactin resin for 2 h at 4 ◦C on a rotating wheel. After incubation, lysates and
resins were transfered to micro spin columns and washed 3 x with 500µl TAP-wash
buffer with 5 sec centrifugation steps at 100 x g between each wash. Subsequently,
samples were eluted by incubation with 500µl TAP-elution buffer for 10min. Eluates
were further incubated with 50 µl anti-FLAG M2 resin for 2 h at 4 ◦C on a rotating wheel.
Following incubation with the anti-FLAG M2 resin, samples were washed once with
500µl TAP-wash buffer and twice with 500µl TBS as mentioned above. For the final
elution of bound proteins, samples were incubated with 200µl FLAG elution buffer for
10min on ice in micro spin columns with several times of gentle mixing.
3.7.4 Analysis of mass-spectrometric data
Raw mass spectrometry data sets were processed with MaxQuant software for
identification and quantification of proteins. For protein identification, peptides were
searched against human protein sequences obtained from Uniprot. Statistical analysis
of processed data sets was performed with Perseus software. Reactome functional
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interaction analysis of enriched co-purified proteins and pathway enrichment analysis
was done with Cytoscape [55] using the ReactomeFIViz plug-in.
3.8 Work with Mus musculus
3.8.1 Animal housing
Mice were kept under standard SPF conditions with a 12 h dark/light cycle, and normal
chow and autoclaved water ad libitum. Isolated DNA from mouse tail tips was used for
genotyping.
3.8.2 Glucose tolerance test
To analyse glucose tolerance mice were fasted for 6 h with supply of drinking water ad
libitum. Afterwards, fasting blood glucose (0min sample) was measured by scratching
the tail tip of mice and sampling a drop of blood with a test strip for determination of
blood glucose with a glucose meter. Mice were weighed and administered with a final
glucose concentration of 2 g/kg by intraperitoneal (IP) injection. Subsequently, blood
glucose was measured after 15, 30, 60, 90 and 120min by withdrawing blood from the
initially scratched tail tip.
3.8.3 Insuin tolerance test
For testing the insulin tolerance, mice were supplied with chow and drinking water ad
libitum before and throughout the experiment. Initial blood glucose (0min sample)
was measured by scratching the tail tip of mice and sampling a drop of blood with
a test strip for determination of blood glucose with a glucose meter. Mice were
weighed and administered with a final insulin concentration of 0.75U/kg by IP injection.
Subsequently, blood glucose was measured after 15, 30, 60, 90 and 120min by
withdrawing blood from the initially scratched tail tip.
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4.1 General phenotypic analysis
After the generation of the Creld2-knockout-mouse, offspring from heterozygous
matings were evaluated for a Mendelian distribution showing a normal distribution [2].
However, due to the mixed background of generated mice, the line was back-crossed
to the C57BL/6JRcc background for a minimum of 10 generations, reaching 95%
C57BL/6JRcc background. Both, male and female Creld2-/- mice were born in
Mendelian ratio (Figure 4.1a). Further, in the assessment of the general Creld2-/-
phenotype, male wild-type and Creld2-/- mice body weights were determined at the
age of 1, 2 and 12-months and show similar weight gains throughout ageing, albeit
Creld2-/- mice weights are slightly reduced (Figure 4.1b). Comparing liver weights
of Creld2-/- and littermate control male mice at 2 and 12-months of age reveals
significantly decreased liver weight in 12-months-old Creld2-/- males (Figure 4.1c).
However, assessment of the liver to body weight ratio in thesemice only shows a slightly
decreased ratio compared to the wild-type (Figure 4.1d).
In addition to the assessment of liver weights, livers of 1-month and 12-months-old
male mice were examined histologically (Figure 4.2). Hematoxylin/Eosin (HE) stained
livers of 1-month-old Creld2+/+ and Creld2-/- mice show no differences in liver tissue
structure (Figure 4.2a). On the other hand, Creld2-/- livers of 12-months-old males
reveal dilation of sinusoids and the presence of vacuoles in hepatocytes, whileCreld2+/+
livers are comparable to those in 1-month-old mice (Figure 4.2b (top)). To test whether
livers of Creld2-/- mice store more lipids than wild-type controls, Oil-red-O stainings
were performed. Indeed, 12-months-old livers show more intensive staining for lipids
in Creld2-/- mice compared to wild-type controls (Figure 4.2b (middle)), indicating that
the observed vesicles in the HE staining are filled with neutral lipids. This is similar
to the initial characterisation of the Creld2-/- mouse [2] and could be validated in this
study. The increased accumulation of vacuoles and lipids in hepatocytes is present
in circa 75% of Creld2-/- animals. Furthermore, livers of 12-months-old mice were
stained against glutamine synthetase (GS) (Figure 4.2b (bottom)), which is assessed
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Figure 4.1: Genotype distribution and comparison of mouse weights. (a) Genotype and
gender distribution of mice born from heterozygous matings (n=17 matings). (b) Body weight
development of Creld2+/+ and Creld2-/- male mice (for 1 and 2-months-old mice n=5–7, for
12-months-old Creld2+/+ mice n=10 and Creld2-/- n=18). (c) Liver weight development of
Creld2+/+ and Creld2-/- male mice. Liver weight of 12-months-old Creld2-/- mice is significantly
reduced. (d) Liver to body weight ratios in 2 and 12-months-old males (n=5 for 2-months-old
mice, for 12-months-old Creld2+/+ n=3 and Creld2-/- n=9 in c-d).
to examine metabolic anomalies in ammonia detoxification [56] and also serves as a
marker for various metabolic liver aberrations [57,58]. In a healthy liver, the expression
of GS is found exclusively in endothelial cells lining hepatic veins and may be present
in another one or two layers of liver parenchymal cells [59].
However, the GS signal in Creld2-/- livers is frequently (approximately 75%) exceeding
the endothelial layer of hepatic veins, which indicates disturbances in liver metabolism.
4.2 Analysis of metabolism
The accumulation of neutral lipids in hepatocytes of 1-year-old Creld2-/- mice might
underlie various aberrant conditions, such as insulin resistance, type II diabetes and
anomalous genetic orchestration of metabolism [44]. To investigate and narrow down
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Figure 4.2: Histological analysis of livers. (a) HE staining of 1-month-old Creld2+/+ and
Creld2-/- male mice (n=2–3). (b) HE (top), Oil-red-O (middle) and GS (bottom) staining of
12-months-old Creld2+/+ and Creld2-/- male mice livers (n=5). HE staining shows disintegrated
liver structure with dilated sinusoids (overview) and vacuolar deposits in hepatocytes (inset)
in Creld2-/- mice. Oil-red-O staining of neutral lipids reveals increased accumulation of lipids
in Creld2-/- livers. Staining against GS displays vacuolar deposits in hepatocytes and diffused
signal for GS.HE: Hematoxilin & Eosin; GS: Glutamine synthetase. Scale bars indicate 100µm.
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potential causes of this steatotic phenotype, mice were subjected to systemic, lipidomic
and molecular analyses of their metabolism.
In addition, the severity of this phenotype was assessed by measuring the inflammation
status in the liver.
4.2.1 Analysis of liver lipid homeostasis
To assess the lipid composition of young (1 month) and old (12 months) Creld2-/-
mice and wild type controls, livers were harvested, total lipids were extracted and
subjected to thin layer chromatography analysis (Figure 4.3.) To observe possible
gender differences in lipid contents, male and female liver lipid extracts were analysed
separately. 12-months-old male mice show significantly increased cholesterol levels,
while other lipid species such as cholesteryl esters, Diacylglycerols (DAGs) and free
fatty acids are elevated in both, young and old male mice. Furthermore, TAG levels
in old mice show no differences in relative lipid abundance when compared to their
wild type controls, whereas young Creld2-/- mice livers show an increased TAG content
(Figure 4.3a). In contrast, analyses of old female mice (Figure 4.3b) indicate no
differences in relative lipid abundance of any lipid species when compared to wild type
mice.
4.2.2 Transcriptional regulation of lipid metabolism genes
For a better understanding of the underlying hepatosteatotis and the differences in liver
lipid composition between Creld2-/- and Creld2+/+ mice, expression analyses of genes
involved in lipid metabolism and homeostasis in the liver were performed. Genes
important for fatty acid oxidation, acylglycerol metabolism, cholesterol storage and
general lipid storage were examined separately for male and female mice (Figure
4.4). The results display significantly reduced peroxisome proliferative activated
receptor gamma coactivator 1 alpha (Pgc1α) expression in male Creld2-/- mice (Figure
4.4a). Pgc1α is a transcription factor playing a major role in energy metabolism by
orchestrating programs responsible for mitochondrial biogenesis and function [60].
Additionally, Pgc1α regulates the expression of enzymes for mitochondrial fatty acid
oxidation [61]. Moreover, dysfunction in the metabolism of acylglycerols are noticeable
in Creld2-/- males as evidenced by decreased levels in apolipoprotein C-II (Apoc2) and
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Figure 4.3: Thin layer chromatography of total lipid extracts from young and old Creld2-/-
and litter mate control mice livers. Lipid content of Creld2-/- mice was normalized to
age-matched wild type controls. Dashed line indicates mean values of Creld2+/+ mice, which
were set to 1. (a) Lipid analysis of 1 month (1 m, orange) and 12 months (12 m, red) old male
mice. Significantly elevated cholesterol contents are observable in 12-months-old males. Free
fatty acids, DAGs and cholesterol esters show increased quantities in 1 and 12 month old mice.
(b) Lipid contents in female mice. No variance in lipid species contents between Creld2+/+ and
Creld2-/- females is visible. Number of analysed mice (n) for each group is indicated in the
figure key. DAG: Diacylglycerol; TAG: Triacylglycerol. Bottom and top of boxes represent the
first quartile (Q1) and third quartile (Q3) with indicated median (bar inside box). Lower and upper
whiskers represent minimum and maximum values within 1.5 x the interquartile range (IQR) of
Q1 or Q3. Closed (black) circles represent statistical outlier. Unpaired, two-tailed student’s t-test
was performed for calculation of p-values. P-values below 0.1 are indicated.
diacylglycerol O-acyltransferase (Dgat2) (Figure 4.4b). Apoc2 is a required cofactor
of lipoprotein lipase for the hydrolysis of TAGs into free fatty acids and DAGs [62, 63],
whereas Dgat2 is responsible for the synthesis of TAGs [64].
In line with the analyses of liver lipid composition, there are gender-specific differences
in gene expression levels. In contrast to male mice, no significant transcriptional
regulation of gene expression is present in female mice. Major differences between
male and female mice are visible in genes responsible for lipid storage (Figure 4.4b).
Here, fat storage-inducing transmembrane protein 2 (Fit2) shows increased expression
in Creld2-/- females compared to the wild type controls, whereas male Creld2-/- mice
show a decrease in Fit2. Additionally, female mice are virtually devoid of fat specific
protein 27 (Fsp27), while males display a high variability in Fsp27 levels.
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4.2.3 Glucose metabolism
The development of liver steatosis may not only be the consequence of multiple
abnormalities in the metabolism but might also entail various aberrations in metabolism
homeostasis [44]. To obtain an insight into the metabolic status of Creld2-/- mice, the
systemic and liver-specific glucosemetabolismwas analysed in 1-year-old mice (Figure
4.5).
To measure systemic glucose metabolism, glucose and insulin tolerance tests were
performed inCreld2-/- and littermate control male mice (Figure 4.5a-b). Here, mice were
administered either glucose or insulin, and the blood glucose levels were measured
over a period of 120min. For analysis of glucose tolerance, mice were fasted for 6 h
prior to injection to establish a fasting blood glucose baseline. The fasting glucose levels
in Creld2+/+ and Creld2-/- mice is virtually equal. However, after application of glucose,
Creld2-/- mice show augmented elevation of blood glucose compared to wild-type
littermates, with highest levels 15min post-glucose administration (Figure 4.5a). To
test the insulin tolerance, mice were not fasted to avoid severe hypoglycemia, so that
no consistent glucose baseline levels could be obtained. Due to the dispersed initial
blood glucose levels, the measured glucose of the insulin tolerance test is displayed in
percent. Blood glucose levels in Creld2+/+ mice drop to approximately 60% after insulin
injection and return almost to the starting value at the end of the observation time.
In contrast, Creld2-/- mice reveal overall reduced blood glucose clearance, reaching
a drop to maximally 75%. The decrease of blood glucose is significantly diminished
Figure 4.4 (preceding page): Gene expression analysis of lipid metabolism components.
Male (left, Ä) and female (right, Ã) mice were analysed separately. (a) Genes responsible for
fatty acid oxidation. Pgc1α is significantly reduced in Creld2-/- males. (b) Expression of genes
involved in acylglycerol metabolism. Creld2-/- male mice show reduced levels of Apoc2 and
Dgat2 with values close to significance. (c) Analysis of genes involved in cholesterol storage.
(d) Marker genes for lipid storage. Female Creld2-/- mice show upregulated expression of Fit2.
Expression results implicate gender-specific differences in Fsp27, which expression is virtually
absent in females. Data set is comprised of n=3–5 for male and n=3–8 for female. Gene
expression levels are represented as housekeeper normalized ∆∆Cq values. Bottom and
top of boxes represent the first quartile (Q1) and third quartile (Q3) with indicated median (bar
inside box). Lower and upper whiskers represent minimum and maximum values within 1.5
x the interquartile range (IQR) of Q1 or Q3. Closed (black) circles represent statistical outlier.
Unpaired, two-tailed student’s t-test was performed for calculation of p-values. P-values below
0.1 are indicated.
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15min post insulin application in Creld2-/- mice compared to the controls. Furthermore,
glucose levels after 120min are still remaining at approximately 85% in Creld2-/- mice
and are not normalizing as fast as in the littermate controls (Figure 4.5b).
To analyse the underlying molecular mechanisms that could explain the differences
in the responses to glucose and insulin, further studies of glucose metabolism were
conducted in the liver of mice because the liver is a key organ for carbohydrate
metabolism.
The activation of the insulin signalling pathway is often defective in insulin resistance
and type II diabetes [65]. After binding of insulin to the insulin receptor, protein kinase
B (Akt) is activated by phosphorylation and stimulates glucose uptake into the cell [66].
Determination of Akt activation is one possible measure to analyse insulin sensitivity
and was therefore analysed by assessing the phosphorylation of Akt 15min post insulin
administration (Figure 4.5c-d). Here, moderately increased P-Akt/Akt ratio levels are
observed in Creld2-/- mice compared to wild-type littermates.
In addition to the study of the insulin signalling pathway on protein level, livers of male
and female mice were analysed for gene expression of two major glucose transporters
(Glut), Glut2 and Glut4 (Figure 4.5e). Glut2 is the main glucose transporter in the
liver [67, 68] and shows slightly reduced expression levels in Creld2-/- males. Glut4
encodes a protein important for transport of glucose across the plasma membrane into
adipocytes and striated muscle [69]. However, Glut4 expression levels in wild-type
livers resembles the ∆∆Cq values of Glut2 in these analyses. Creld2-/- males reveal
significantly decreasedGlut4 expression compared to the wild-type. Deficiency of Glut4
was reported to be an indirect cause for increased liver lipid production in mice [70].
Defects in insulin signalling or glucose uptake could influence the energy metabolism,
leading to reduced ATP synthesis. Therefore, the content of ATP in 1-year old mice
was determined (Figure 4.5f). ATP levels are reduced in Creld2-/- males, albeit not
significant due to a strong variability of ATP levels in Creld2+/+ male mice. For female
mice, no definite differences are visible because of high variation in Creld2-/- mice.
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Figure 4.5: Analysis of glucose metabolism and energy state in 1-year-old mice. (a)
Glucose tolerance test in Creld2+/+ (n=9) and Creld2-/- (n=10) male mice. Glucose level is
displayed in mmol/l. Creld2-/- mice show increased blood glucose levels after 15min to 30min
of glucose administration compared to wild type littermates. (b) The insulin tolerance test shows
a significant reduction of glucose uptake into cells 15min after insulin injection in Creld2-/- males
(n=9). Glucose uptake in Creld2+/+ mice (n=8) is increased by approximately 20%. Blood
glucose is presented as percentages.(c) Insulin signalling pathway activation analysis in livers
15min after insulin administration shows an increased P-Akt/Akt ratio in Creld2-/- mice. (d)
Immunoblots of liver samples described in (c). (e) Measurement of liver ATP levels. Liver ATP
abundance is displayed in µM for male (left) and female (right) mice. ATP levels in Creld2-/-
males tend to be decreased compared to wild type controls. f) Analysis of transporter genes
for glucose uptake into the cell. Gene expression of Glut4 in Creld2-/- males is significantly
reduced in contrast to wild-type males (for males n=4–5; for females n=7–8). Expression of
Glut2 is neither altered in females nor in males (for males n=3–5; for females n=6–8). Values in
(a-b) are represented as means±SD. Gene expression levels are represented as housekeeper
normalized∆∆Cq values. Coloured circles represent individual mice. Bottom and top of boxes
represent the first quartile (Q1) and third quartile (Q3) with indicated median (bar inside box).
Lower and upper whiskers represent minimum andmaximum values within 1.5 x the interquartile
range (IQR) of Q1 or Q3. Closed (black) circles represent statistical outlier. Unpaired, two-tailed
student’s t-test was performed for calculation of p-values. P-values below 0.1 are indicated.
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4.3 Analysis of liver injury status
Due to the developing liver steatosis and metabolic imbalances in 1-year-old Creld2-/-
mice, the livers of these mice were analysed for their state of health. For this purpose
gene expression levels of markers for cell viability and inflammation were determined
(Figure 4.6). As a measure of general cell cycle in the liver, gene expression of
extracellular signal-regulated kinase 1 (Erk1) andErk2, which are involved in cell growth
[71] and death receptor 5 (Dr5), a marker for apoptosis, were analysed (Figure 4.6a).
Male Creld2-/- mice show a slight reduction in Erk2 expression compared to wild-type
males. Erk1 and Dr5 expression in Creld2-/- males and females is similar compared to
Creld2+/+ mice, with Dr5 showing slightly reduced gene expression in Creld2-/- females
in comparison to the wild-type controls.
Progressing liver steatosis is the basis for the development of NAFLD, which is a chronic
inflammatory liver disease. In NAFLD, initially harmless liver steatosis can progress to
steatohepatitis, fibrosis and cirrhosis [45]. Hence, the liver is experiencing increasing
levels of inflammation and tissue damage in the course of NAFLD progression.
Therefore, the degree of liver damage was assessed by determining the expression
of acute phase response (APR) genes, which are induced upon tissue injury [72]. APR
components serum amyloid P-component (Apcs) and serum amyloidA-3 protein (Saa3)
were analysed for gene expression (Figure 4.6b). Both genes show similar expression
in Creld2+/+ and Creld2-/- mice of the same gender, but display increased expression in
female mice compared to males.
The assessment of APR components is suited to determine the injury or inflammation
status of the liver and also allows to monitor occurring inflammatory responses
days later [72]. However, APR induction can be missing in the case of defective
upstream signalling, which are pro-inflammatory cytokines. Therefore, the inflammation
status of 1-year-old livers was assessed by measuring gene expression levels of
pro-inflammatory cytokines (Figure 4.6c). Albeit the presence of a hepatosteatosis and
a potential immune cell infiltrate, tumor necrosis factor alpha (Tnfα) and interleukin 6
(Il6) show decreased expression in Creld2-/- male mice compared to wild-type males
and interleukin 1β (Il1β) in Creld2-/- females displays downregulation in comparison to
Creld2+/+ female controls.
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Figure 4.6: Determination of liver health state in aged mice. Male (left, Ä) and female
(right, Ã) mice were analysed separately. (a) Expression levels of genes involved in cell
proliferation and apoptosis, namely Erk1, Erk2 and Dr5, respectively. (b) Analysis of acute
phase response genes as tissue damage response marker. Female mice, independent of
genotype, express more Apcs and Saa3 than males. (c) Assessment of liver inflammation.
Tnfα and Il6 gene expression is reducedb in male Creld2-/- mice and Il1β levels are decreased
in female Creld2-/- mice compared to their wild-type controls. Gene expression levels are
represented as housekeeper normalized∆∆Cq values. Bottom and top of boxes represent the
first quartile (Q1) and third quartile (Q3) with indicated median (bar inside box). Lower and upper
whiskers represent minimum and maximum values within 1.5 x the interquartile range (IQR) of
Q1 or Q3. Closed (black) circles represent statistical outlier. Unpaired, two-tailed student’s t-test
was performed for calculation of p-values. P-values below 0.1 are indicated.
48
4 Results
The main cytokine producing cells in the liver are Kupffer cells. Thus, the abundance
of Kupffer cells in livers of 1-year-old Creld2-/- male mice was compared to those of
age-matched wild-type controls (Figure 4.7a). However, Creld2-/- livers rather show an
increase of Kupffer cell numbers when compared to Creld2+/+ mice. This hints towards
defects in activation of Kupffer cells or infiltrating macrophages from the bone-marrow.
To test whether macrophage induction is dysfunctional due to Creld2 deficiency in
general, bone-marrow derived macrophages (BMDMs) of 1-year-old Creld2+/+ and
Creld2-/- males were treated with Lipopolysaccharide (LPS) to stimulate the production
of pro-inflammatory cytokines and gene expression of Tnfα, Il1β and Il6 was assessed
after 4 h and 8 h of LPS treatment (Figure 4.7b). BMDMs of both genotypes display
peaking cytokine gene expression after 4 h, with decreasing expression levels at 8 h
of LPS stimulation, but no differences in transcript levels between both genotypes are
noticeable.
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Figure 4.7: Analysis of Kupffer cells and macrophage activation. (a) Determination of
Kupffer cell abundance in 1-year-old Creld2+/+ (n=3) and Creld2-/- (n=9) male mice via flow
cytometry. Kupffer cells were determined by gating on single, live, CD45+, CD11b low,
F4/80+Tim4+ cells. (b) Analysis of bone-marrow derived macrophage (BMDM) activation after
LPS treatment. Gene expression of Tnfα, Il1β and Il6 in BMDMs from 1-year-oldCreld2+/+ (n=4)
and Creld2-/- (n=3) male mice shows no differences between the genotypes. Gene expression
is represented as housekeeper normalized∆∆Cq values relative to the 0 h wild-type controls.
Bottom and top of boxes represent the first quartile (Q1) and third quartile (Q3) with indicated
median (bar inside box). Lower and upper whiskers represent minimum and maximum values
within 1.5 x the interquartile range (IQR) of Q1 or Q3. Closed (black) circles represent statistical
outlier. Unpaired, two-tailed student’s t-test was performed for calculation of p-values. P-values
below 0.1 are indicated.
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4.4 Steady state UPR in 1-year-old mice
The development of liver steatosis is frequently correlated with malfunctions in the
UPR pathways. Besides inducing genes for the amelioration of ER stress, each of
these pathways induces sets of genes involved in fatty acid metabolism [36, 38, 31].
Since Creld2 is induced by Atf6α during ER stress and thus potentially plays a role
in the regulation of the UPR, 1-year-old mice livers were analysed for their steady
state UPR to determine whether Creld2-/- mice exhibit an aberrant ER stress status.
For general assessment of ER stress the expression of chaperones Grp78, Grp94
and the apoptosis inducer Chop were analysed (Figure 4.8a). Grp94 expression is
significantly increased in male Creld2-/- mice, whereas Creld2-/- females show slightly
elevated Grp94 expression. Grp78 mRNA expression is not altered between the two
genotypes inmales but is marginally reduced inCreld2-/- females compared to littermate
controls, which is confirmed by unaltered Grp78 protein expression (Figure 4.8b).
Furthermore, activation of the Atf6α, Ire1α and Perk pathways were analysed (Figure
4.8c,d,e). No significant differences in gene expression of Atf6α (Figure 4.8c) or Ire1α
pathway (Figure 4.8d) downstream targets could be observed inmalemice compared to
littermate controls. However, female Creld2-/- mice show an upregulation of Ire1α and
decreased sXbp1 levels (Figure 4.8d). Activation of the Perk pathway was assessed by
immunoblotting through determination of the phosphorylation status of Perk and eIF2α,
as well as expression of Gadd34 (Figure 4.8e). These analyses show no substantial
differences between wild-type and Creld2-/- mice. Still, a minor reduction of Gadd34
expression in female Creld2-/- mice as compared to Creld2+/+ females is noticeable.
4.5 Analysis of bones
4.5.1 Analysis of bone structure
Recently, Creld2 was reported to be upregulated in chondrocytes experiencing ER
stress, as well as to be a component of the ECM in the epiphyseal growth plate [50].
Furthermore, Briggs et al. [73] state that cartilage-specific Creld2-/- mice exhibit growth
plate dysplasia. However, these findings are unpublished yet.
To analyse the growth plate and the overall bone structure phenotype in Creld2
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knockout mice, femurs of 1-month-old mice were analysed histologically (Figure
4.9a). Masson-Goldner trichrome stained Creld2-/- bones show no apparent
differences in overall mineralised bone structure (green) compared to wild-type controls.
However, Creld2-/- mice occasionally display increased innervation of bone matrix by
chondrocytes. Additionally, in contrast to wild-type mice, Creld2-/- mice frequently show
disrupted columnar alignment of chondrocytes in the epiphyseal growth plate and a
larger hypertrophic zone, which is composed of roundly shaped chondrocytes.
In another recent report, it was found that Creld2 enhances bone formation and matrix
mineralisation in vitro [51]. To investigate the effect of Creld2 on bone formation,
femoral bone mineral density (BMD) was assessed in 1-year-old mice, since young
mice show no apparent histological abnormalities regarding bone mass. Further, an
osteopenic phenotype in Creld2-/- mice would be visible more likely during ageing. The
micro-CT analyses of bones that were performed in collaboration with the group of prof.
Inada (Tokyo university of agriculture and technology, Japan) reveal a higher BMD in
male and female Creld2-/- mice compared to the wild-type, indicating a development of
osteopetrosis in Creld2-/- mice (Figure 4.9b,c).
Figure 4.8 (preceding page): Analysis of UPR pathways in livers of 1-year-old mice. Male
(left, Ä) and female (right, Ã) mice were analysed separately. (a-b) Determination of general
ER stress. (a) Gene expression of Grp78, Grp94 and Chop. Incresed levels of Grp94 are
present inCreld2-/- mice of both genders with significant levels in males. For male wild-typemice
n=3–4 and Creld2-/- n=4–5. For female Creld2+/+ n=2, except for Grp94 (n=7). Creld2-/-
female results consist of n=5, except for Grp94 (n=8). (b) Protein expression of UPR regulator
Grp78 is similar in both genotypes and genders (male Creld2+/+: n=4–7, Creld2-/-: n=5–10;
female Creld2+/+: n=3, Creld2-/-: n=5). (c) Atf6α pathway induced genes Edem1 and Derl3
do not show genotypic or gender specific differences in expression levels (n=3–5 for male
and n=5–8 for female Creld2+/+ and Creld2-/- mice). (d) Expression of genes regulated by the
Ire1αpathway. A trend of increased Ire1α and decreased sXbp1 is present in Creld2-/- female
mice (n=5–8) compared to wild-type controls (n=3–6). In male Creld2+/+ (n=3–4) and Creld2-/-
(n=5) mice no differences are evident. (e) Protein abundances of components of the Perk
pathway, respectively. The steady state assessment of Grp78 and Perk pathway components
displays equal levels of relative protein abundances in males of both genotypes. For male
Creld2+/+ n=4–7 and Creld2-/- n=5–10. Female wild-type mice n=3 and Creld2-/- mice by n=5.
(f) Representative immunoblots of proteins displayed in (b) and (e). Gene expression levels are
presented as normalized ∆∆Cq values. Bottom and top of boxes represent the first quartile
(Q1) and third quartile (Q3) with indicated median (bar inside box). Lower and upper whiskers
represent minimum and maximum values within 1.5 x the interquartile range (IQR) of Q1 or Q3.
Closed (black) circles in (a-e) represent statistical outlier. Unpaired, two-tailed student’s t-test
was performed for calculation of p-values.
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4.5.2 Analysis of the hematopoietic stem cell niche
To further determine the severity and potential impact of the developing osteopetrosis
in Creld2-/- mice on the bone-marrow niche, the femoral and tibial bone-marrow
in Creld2+/+, Creld2+/- and Creld2-/- mice was analysed via flow cytometry (Figure
4.10). A progressing increase in bone mass eventually causes space constraints
for blood vessels and bone-marrow cells and results in decreasing cell numbers
in the bone-marrow niche. To analyse the progression of the osteopetrosis, total
bone-marrow cell number per leg was determined, showing no differences between the
three genotypes (Figure 4.10a). Despite the total cell numbers being normal in Creld2-/-
mice, the increased bone mass might have an impact on the hematopoietic stem cell
(HSC) niche. Thus, different HSC populations were quantified. First, bone-marrow
cells were identified by gating to Lineage negative (Lin-) Sca1+ cKit+ (LSK) cells,
which is the surface marker expression profile by which all HSCs are defined (Figure
4.10b,c). Further gating identifies different HSC subpopulations by the expression of
CD48 and CD150 [74] (Figure 4.10d). Interestingly, while LSK cells in Creld2+/- and
Creld2-/- bone-marrow express the green fluorescent protein (GFP) reporter, indicating
a potential need for Creld2 by the cells (Figure 4.10c), no deviations in LSK or HSC
population cell numbers is observed among the three genotypes (Figure 4.10d). Taken
together, these results suggest that despite the increased bone mineral density, the
osteopetrosis has not progressed to a pathogenic status.
Figure 4.9 (preceding page): Analysis of bones in 1-month and 1-year-oldmice. (a)Mason
Goldner staining of 1-month-old Creld2+/+ and Creld2-/- male mice femurs. Top panel depicts an
overview of the proximal (hip joint) femur. Bottom panel shows a magnification of the epiphyseal
growth plate. Chondrocytes in the proliferating zone ofCreld2-/- show deviations in the columnar
alignment and display a wider hypertrophic zone (roundish cell shape) when compared to the
wild-type. Scale bars indicate 100µm. Representative for n=2–3. (b) Micro-CT radiographic
analysis and (c) quantification of bone mineral density in 1-year-old male (left, Ä) and female
(right, Ã) femurs. Creld2-/- mice exhibit increased bone mineral density in the proximal (hip
joint) and distal (knee joint) part of the femur. n=3 for Creld2+/+ and n=5 for Creld2-/- mice in
both genders. Bottom and top of boxes represent the first quartile (Q1) and third quartile (Q3)
with indicated median (bar inside box). Lower and upper whiskers represent minimum and
maximum values within 1.5 x the interquartile range (IQR) of Q1 or Q3. Closed (black) circles
represent statistical outlier. Unpaired, two-tailed student’s t-test was performed for calculation
of p-values. P-values below 0.1 are indicated.
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Figure 4.10: Bone-marrow analysis in 1-year-old male mice. (a) Determination of whole
cell numbers per leg in bone-marrow of Creld2+/+, Creld2+/- and Creld2-/- mice. (b) Gating
strategy to identify LSK and HSC lineages. Gated on single live cells. (c) GFP expression
in LSK cells. (d) Determination of bone-marrow HSCs (hematopoietic stem cells) in Creld2+/+
(n=3), Creld2+/- (n=6) and Creld2-/- (n=9) mice. n=3 for Creld2+/+, n=6 for Creld2+/- and n=9
for Creld2-/-. Two-way Anova was used for statistical evaluation. Bottom and top of boxes in
(a) and (d) represent the first quartile (Q1) and third quartile (Q3) with indicated median (bar
inside box). Lower and upper whiskers represent minimum and maximum values within 1.5 x
the interquartile range (IQR) of Q1 or Q3. Closed (black) circles represent statistical outlier.
4.6 In vitro analysis of the UPR
The development of NAFLD in Creld2-/- mice may be the consequence of diverse
factors, for example, obesity or genetic disorders. Creld2 is known to be induced
by ER stress due to an ERSE consensus sequence in its promoter [10]. Moreover,
abnormal UPR regulation is repeatedly associated with liver steatosis [75,76]. Thus, the
development of liver steatosis inCreld2-/- mutants suggests that Creld2 is involved in the
regulation of the UPR. However, UPR analyses in livers of 1-year-old mice did not show
any significant dysregulations in Creld2-/- mice. A possible reason for this may be that
the liver steatosic phenotype is not 100% penetrant, which might conceal occuring UPR
dysregulations, since analyses of livers were performed on mice cohorts without a prior
histological assessment of steatosis. To delineate the functional and regulatory role
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of Creld2 in the UPR, an in vitro system was utilised analysing wild-type and Creld2-/-
cells under ER stress. The three UPR pathways are orchestrated in a sophisticated
manner to resolve ER stress [15] and reveal distinct responses to different ER stress
conditions [77]. To encompass the intricate facets of UPR regulation, several ER stress
models and different ER stressors were employed to investigate UPR pathways for
aberrant regulation in Creld2-/- cells. MEFs were used due to their heterogeneous
nature and primary cell line characteristics enabling the in-depth study of complex
pathways in genetically modified cells while conserving physiological properties, which
mimic the complex interaction of various cell types present in an organ [78].
4.6.1 Chronic ER stress
Naturally, cells in an organism constantly encounter ER stress due to the permanent
need for protein synthesis in response to metabolic demands. Therefore, cells need
to adapt to ER stress and to relieve the stress for the establishment of normal cell
function by activating the UPR [30]. In disease conditions, as in diabetes or NAFLD,
it is frequently implicated that cells are unable to abolish the experienced ER stress,
which eventually leads to disease progression over time [13]. To study the involvement
of Creld2 in UPR regulation, wild-type and Creld2-/- MEFs were challenged with low
doses of either thapsigargin (Tg) (2.5–10 nM) or Tm (25–100ng/ml) to induce chronic
ER stress over 1–3 days. Challenged cells were analysed for their viability and the
regulation of UPR pathways on transcriptional as well as translational level.
4.6.1.1 Cell viability during chronic ER stress
To assess the ability of Creld2-/- MEFs to sustain and to adapt to chronic ER stress,
relative cell numbers as an indicator for cell proliferation were determined via crystal
violet staining after treatment with different concentrations of Tg or Tm for up to 3 days
(Figure 4.11). Wild-type MEFs show proliferation after treatment with up to 10 nM Tg
(Figure 4.11a) and only start stagnating in growth when challenged with 50–100ng/ml
Tm (Figure 4.11b). In contrast, the chronic stress results in significantly reduced cell
numbers in Creld2-/- MEFs after two days of treatment with any dose of Tg (Figure
4.11a) or Tm (Figure 4.11b), indicating not only growth stagnation but also apoptosis.
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Due to the ability of wild-type MEFs to tolerate and adapt to even the highest
concentrations of Tg (10 nM) or Tm (100 ng/ml) tested, while Creld2-/- cells are unable
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Figure 4.11: Analysis of cell viability during chronic ER stress. (a) Treatment of Creld2-/-
and Creld2+/+ MEFs with various Tg concentrations (top to bottom: 0 nM, 2.5nM, 5 nM, 10 nM)
for up to 2 days. Creld2-/- MEFs show significant reduction in cell numbers compared to
wild-type control after 2 days of treatment with any Tg concentration. (b) Same as in (a) but
treatment of MEFs with Tunicamycin (top to bottom: 0 ng/ml, 25 ng/ml, 50 ng/ml, 100 ng/ml) for
up to 3 days. Creld2-/- MEFs show significant reduction in cell numbers compared to wild-type
control after 2 days of treatment with 25–50ng/ml Tunicamycin and already after day 1 with
100 ng/ml. Data are represented as mean±SD. P-values were calculated using unpaired,
two-tailed Student’s t-test. n=12–16, except for 100 ng/ml Tunicamycin (n=6) per genotype.
to maintain their viability under these conditions, further chronic ER stress studies were
performed using the highest Tg and Tm concentrations.
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4.6.1.2 Regulation of ER stress markers during chronic ER stress
All of the three UPR pathways induce different gene expression programs to resolve ER
stress. However, there are downstream targets, which are induced by a combination
of two or more UPR branches [16]. Here, such targets are categorised as general
ER stress marker. Analysis of these markers gives an insight into the efficiency of the
UPR. Gene expression analyses ofGrp78,Grp94 andChop show an initial upregulation
and subsequent reduction of those genes in Tg and Tm treated cells, whereas Dr5
remains unaltered in both genotypes (Figure 4.12a). However, ER stress induction with
Tm elicits a stronger upregulation of Grp78, Grp94 and Chop than treatment with Tg.
Contrary to the dynamically regulated transcript, Grp78 protein levels increase slightly
after Tg or Tm challenge and remain on the same level (Figure 4.12b,c). Chop protein
expression is upregulated by Tm treatment resembling the gene expression behaviour.
Interestingly, Creld2-/- cells display slightly decreased Chop protein levels during steady
state when compared to wild-type controls. Nevertheless, Creld2-/- MEFs upregulate
Chop after ER stress induction similar to Creld2+/+ cells (Figure 4.12c).
4.6.1.3 Perk pathway regulation during chronic ER stress
For the analysis of the Perk pathway, gene expression of Perk and Gadd34 was
assessed. Gadd34 is induced by Chop but belongs to the Perk pathway because
it dephosphorylates eIF2α, which is a direct target of Perk [20]. Both treatments
induce Perk expression in wild-type cells to the same extent, whereas Perk is not
upregulated in Creld2-/- MEFs, albeit not significant due to high variability in fibroblast
clones. Gadd34 shows equal induction in both genotypes (Figure 4.13a) and reflects
the gene expression pattern of Chop (Figure 4.12a). However, on protein level
Gadd34 remains unaltered throughout the experiment (Figure 4.13c). Furthermore,
Perk pathway activation was analysed by determination of the phosphorylation state of
eIF2α (Figure 4.13c), which remains unaltered in both genotypes.
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Figure 4.12: Regulation of general ER stress maker during chronic ER stress. (a) Gene
expression analysis ofGrp78,Grp94,Chop andDr5 inCreld2+/+ (n=5) andCreld2-/- (n=8)MEFs.
Transcriptional induction of Grp78 is reduced at 24 h of Tg and 48h of Tm treatment in Creld2-/-
fibroblasts compared to the wild-type controls. Gene expression is presented relative to the 0 h
controls, which were set to 1. (b-c) Immunoblot analysis and quantification of Grp78 and Chop
protein levels. Coloured circles represent individual MEF clones (Creld2+/+ and Creld2-/-, n=3).
Protein levels were normalized to β-Actin and presented relative to the 0 h wild-type controls,
which were set to 1. P-values below p=0.1 are indicated. Gene and protein expression is
presented as mean±SD. P-values were calculated using unpaired, two-tailed Student’s t-test.
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Figure 4.13: Perk pathway regulation during chronic ER stress. (a) Gene expression
analysis of Perk and Gadd34 in Creld2+/+ (n=5) and Creld2-/- (n=8) MEFs. Transcriptional
induction of these genes is not altered inCreld2-/- fibroblasts compared to the wild-type controls.
Gene expression is presented relative to the 0 h controls, which were set to 1. (b) Immunoblot
analysis of Perk pathway activation by assessment of Gadd34 and phosphorylated eIF2α
protein levels. c) Quantification of immunoblots in (b). Coloured circles represent individual
MEF clones (Creld2+/+ and Creld2-/-, n=3). Protein levels were normalized to β-Actin, ratios of
phosphorylated to unphosphorylated proteins were determined and presented relative to the 0 h
wild-type controls, which were set to 1. P-values below p=0.1 are indicated. Gene and protein
expression is presented as mean±SD. P-values were calculated using unpaired, two-tailed
Student’s t-test.
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4.6.1.4 Atf6α pathway regulation during chronic ER stress
In the assessment of Atf6α pathway activation, gene expression of Atf6α, Edem1
and Derl3 was measured (Figure 4.14a). Furthermore, Creld2 expression in Creld2+/+
cells and GFP expression in Creld2-/- cells was assessed since the GFP reporter
gene replaces the endogenous Creld2 locus in Creld2-/- mice. Atf6α shows a minor
increase of gene expression after 24 h of Tg or Tm treatment, followed by a decrease of
expression. TomeasureAtf6α transcriptional activity,Creld2 andGFP gene expression
was measured. Creld2 displays strong upregulation after challenge with either ER
stressor, followed by a decline close to baseline levels after 48 h of Tg treatment
and a slower decrease in cells stressed with Tm for 48 h and 72 h. However, gene
expression of the reporterGFP shows only a minor induction when compared to Creld2
transcripts. Moreover, Creld2-/- MEFs reveal significantly reduced induction of Edem1
and Derl3 after 24 h Tg and 48 h Tm treatment in comparison to wild-type cells. The
gene expression induction of Creld2 and the insignificant induction of GFP can be
confirmed by immunoblot probing against Creld2 and GFP (Figure 4.14b,c). While
Creld2-/- cells do not show an elevation of GFP, Creld2 protein expression level is
increased 24h after the beginning of treatment and is maintained until the end of
observations. Furthermore, treatment with Tm, an inhibitor of N-glycosylation, results
in a double band when immunoblotting against Creld2. The lower protein band, likely
being the unglycosylated form of Creld2, confirms previous findings suggesting that
Creld2 is a glycoprotein [10].
4.6.1.5 Ire1α pathway regulation during chronic ER stress
To analyse Ire1α pathway induction, Ire1α gene expression was determined and
shows slight upregulation in cells challenged with Tm for 24 h and 48 h (Figure 4.15).
Additionally, the mRNA level of sXbp1 was assessed to measure Ire1α activation.
sXbp1 abundance is elevated at 24 h in both treatments and declines afterwards.
However, sXbp1mRNA is not falling to the baseline level but plateaus at approximately
the 15-fold of the initial value in the wild-type MEFs and circa 10-fold in Creld2-/- cells.
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Figure 4.14: Atf6α pathway during chronic ER stress. (a) Gene expression analysis
of Atf6α, Creld2 in Creld2+/+ and GFP in Creld2-/-, Edem1 and Derl3 in MEFs. GFP
induction is significantly reduced in Creld2-/- MEFs compared to Creld2 in Creld2+/+ fibroblasts.
Transcriptional induction of Edem1 is significantly lower in Creld2-/- fibroblasts at 24 h of Tg and
48h of Tm treatment compared to the wild-type controls. Derl3 shows diminished expression in
Creld2-/- MEFs. Gene expression is presented relative to the 0 h controls, which were set to 1.
n=5 for wild-type and n=8 for Creld2-/- MEFs. (b-c) Immunoblot analysis (b) and quantification
of immunoblots (c) of Creld2 and GFP protein levels. GFP expression in Creld2-/- cells is not
induced during Tg or Tm challenge. Coloured circles represent individual MEF clones (Creld2+/+
and Creld2-/-, n=3). Protein levels were normalized to β-Actin and presented relative to the 0 h
controls, which were set to 1. P-values below p=0.1 are indicated. Gene and protein expression
is presented asmean±SD. P-values were calculated using unpaired, two-tailed Student’s t-test.
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Figure 4.15: Regulation of the Ire1α pathway during chronic ER stress. Gene expression
analysis of Ire1α and sXbp1 in Creld2+/+ (n=5) and Creld2-/- (n=8) MEFs. Gene expression
is presented relative to the 0 h controls, which were set to 1. P-values below p=0.1 are
indicated. Gene expression is presented as mean±SD. P-values were calculated using
unpaired, two-tailed Student’s t-test.
4.6.2 ER stress recovery
Ongoing research of UPR pathways reveals increasing importance of the UPR for the
maintenance of healthy organ function. One approach to investigate the UPR is the
analysis of knockout mice deficient in the main sensors Atf6α [25], Perk [79] or Ire1α
[36]. Another method implies the use of cultured cells in which the UPR is induced by
challenging cells with different ER stressors. However, in vitro studies usually focus
on analysing the UPR under conditions of steady acute [30] or chronic ER stress [80].
Only little research was carried out regarding the investigation of ER stress recovery
in mammalian cells [25] or plants [81], making a transfer of results and experimental
set up more challenging. Therefore, experimental conditions had to be established to
study the ability of wild-type and Creld2-/- cells to recover after a short pulse of stress,
which would rather recapitulate physiological conditions.
4.6.2.1 Establishment of the ER stress recovery model
A critical aspect in studying ER stress recovery is the duration of ER stress induction,
which on the one hand should be sufficient to trigger a decent UPR activation, but on
the other hand enable cells to overcome this burden, since it is known that prolonged,
strong ER stress irreversibly leads to apoptosis [82,83].
For this purpose Creld2+/+ and Creld2-/- MEFs were challenged with 1 µM Tg for up to
63
4 Results
8h. Transcriptional activation of UPR components was assessed during the treatment
and cell viability was determined 5 days after treatment (Figure 4.16). Here, cell viability
served as an indicator of the capability of cells to cope with and diminish the induced ER
stress and thus cells displaying similar cell numbers as the untreated controls five days
after treatment would be considered to be recovered. Cells that show a reduction in
relative cell numbers after the recovery phase, would still be burdened with ER stress
and therefore either be unable to reach the same proliferation rate or even become
apoptotic. In these assays Creld2+/+ cells show no differences in cell numbers after Tg
challenge ranging from 1–4h compared to the wild-type untreated controls. However,
Creld2-/- MEFs display significantly reduced relative cell numbers when treated for
2 h and 4h with Tg compared to wild-type cells. After 8 h treatment, both genotypes
show decreased cell numbers, indicating that cells experienced excessive ER stress
(Figure 4.16a). For the assessment of the Tg challenge duration, which is sufficient
for the activation of all three UPR pathways, gene expression of selected pathway
components was determined during the treatment time. ER stress marker Grp78 and
Chop show an upregulation already after 1 h of Tg treatment (Figure 4.16b). This is also
observed for Gadd34 in the Perk pathway, whereas Perk expression itself is increasing
at 4 h (Figure 4.16c). Atf6α pathway components Edem1, Derl3 and Creld2 start to
be upregulated notably after 4 h Tg, while Atf6α shows first upregulation after 2 h of
treatment (Figure 4.16d). An explanation for the delayed induction of Edem1, Derl3
and Creld2 might be the initial processing of Atf6α in the Golgi, which is needed to
release the transcriptionally active form of Atf6α. Furthermore, as observed in the
chronic ER stress model (Figure 4.14a-c), the expression of GFP is not induced in
the same amplitude as Creld2. Similar to ER stress marker genes and Gadd34, 1 h Tg
treatment leads to the activation of the Ire1α pathway, indicated by increasing sXbp1
levels. Notably, sXbp1 levels peak at 4 h , but are reduced thereafter to levels observed
after 1 h Tg treatment. Ire1α displays upregulation after 4 h followed by a decrease in
gene expression at 8 h of treatment (Figure 4.16e).
In considerations of choosing the appropriate ER stress pulse duration, the cell viability
analyses narrow down the time span to 2–4 h, since Creld2+/+ cells show equal
proliferation rates as the untreated controls, while Creld2-/- MEFs fail to do so. For
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a full UPR activation the induction of ER stress marker genes, as well as most UPR
pathways, 1 h is sufficient. Although Atf6α pathway induction is initiated after 2 h, a
complete response is seen only after 4–8 h. Taking the observed differences in cell
viability and the time-frame of UPR initiation into account, a 2 h pulse of Tg was used
in subsequent experiments to analyse ER stress recovery.
To determine how wild-type and Creld2-/- MEFs cope with a short but strong ER
stress stimulus provoked by Tg and how the UPR machinery is orchestrated to enable
recovery of cells, the ER stress markers and components of all three UPR pathways
were analysed on transcriptional and translational level over a period of up to 46 h post
2 h ER stress challenge with 1 µM Tg.
4.6.2.2 Marker regulation during ER stress recovery
During ER stress recovery (Figure 4.17a) Grp94 and Chop gene expression is
upregulated after the Tg pulse and slowly decreases over time. This behaviour
of gene expression is observed in both genotypes. However, Creld2-/- cells show
reduced Grp78 and Grp94 gene expression levels the later recovery phase compared
to Creld2+/+ MEFs. Furthermore, Creld2-/- cells display increased Dr5 expression at the
beginning and the end of the recovery phase. Additionally, protein expression of Grp78
and Chop was assessed (Figure 4.17b,c). Notably, initial Grp78 levels show a 2-fold
increase in Creld2-/- cells in comparison to the wild-type and also Chop expression
starts to increase in Creld2-/- MEFs after 10 h, while Creld2+/+ cells reveal steady Chop
levels until 30 h with reduction of Chop at 48 h.
Figure 4.16 (preceding page): Establishment of the ER stress recovery model in MEFs.
(a) Analysis of cell viability after acute ER stress. Creld2-/- (n=8) and Creld2+/+ (n=5) MEFs
were treated with 1 µM Tg for 0–8 h with subsequent incubation without Tg for 5 days following
assessment of viability. Creld2-/- cells show significant reduction in cell numbers compared to
the wild-type control after 2 h and 4h of Tg challenge. (b) Gene expression of Grp78 and Chop
is induced in MEFs after 1 h of Tg incubation. (c) Perk pathway activation. Gadd34 is induced
after 1 h Tg treatment. (d) Transcriptional upregulation of Atf6α pathway components is begins
after 4 h Tg treatment. (e) Ire1α pathway activation. sXbp1 expression is induced after 1 h Tg
challenge and increases until 4 h followed by a reduction at time point 8 h. Gene expression
is presented as mean±SD relative to the 0 h controls, which were set to 1. Coloured circles
represent individual MEF clones (n=3 for wild-type and n=4 for Creld2-/- MEFs, except for Ire1α,
where n=2 for Creld2+/+ and n=3 for Creld2-/-. P-values below p=0.1 are indicated. P-values
were calculated using unpaired, two-tailed Student’s t-test.
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Figure 4.17: Regulation of ER stress markers during ER stress recovery. (a) Gene
expression analysis of Grp78, Grp94, Chop and Dr5 in Creld2+/+ (n=10, except for Dr5 where
n=3) and Creld2-/- (n=8, except of Dr5 where n=3) MEFs. Grp78 and Grp94 show significantly
reduced induction after 10–48 h in Creld2-/- fibroblasts compared to the wild-type controls. Dr5
expression is elevated in Creld2-/- MEFs at 6 h and 48 h. (b) Immunoblot analysis and (c)
quantification of Grp78 and Chop. Creld2-/- cells show upregulated Grp78 from 0–10h and
elevated Chop levels after 10–48h. Protein levels were normalized to β-Actin. Coloured
circles represent measured MEF clones (for Grp78 n=2 and for Chop n=1 for both genotypes).
Gene expression and protein quantification data are presented as mean±SD. P-values were
calculated using unpaired, two-tailed Student’s t-test.
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4.6.2.3 Perk pathway regulation during ER stress recovery
Further differences in the UPR are noticeable in the Perk pathway (Figure 4.18). While
gene expression of Perk and Gadd34 in Creld2-/- cells are similar to wild-type cells
(Figure 4.18a), activation of Perk and eIF2α on protein level differ between the two
groups (Figure 4.18c). Under steady state, Creld2-/- MEFs show reduced P-Perk/Perk
and P-eIF2α/eIF2α ratios. After ER stress induction, wild-type cells display an increase
of the P-Perk/Perk ratio at 48 h, whereas Creld2-/- cells show no increase in Perk
phosphorylation ratio from 6–48h. In addition, wild-type MEFs exhibit increasing
P-eIF2α/eIF2α ratios until 10 h of the experiment, which is followed by a decrease to
baseline values after 30 h. In contrast, Creld2-/- cells show a delayed phosphorylation
of eIF2α with a peak after 30 h without reaching baseline levels even after 46 h (Figure
4.18b,c).
4.6.2.4 Atf6α pathway regulation during ER stress recovery
In the Atf6α pathway Creld2 expression peaks at 30 h of experiment with extents of
15-fold , whereas GFP gene expression in Creld2-/- cells is marginal during recovery
(Figure 4.19a). Reduced induction of GFP in Creld2-/- cells recovery is similar to
what has been observed in the chronic ER stress model (Figure 4.14a) and in the
establisment of the ER recovery model (Figure 4.16d). The same is true on protein
level, where GFP induction is not detectable (Figure 4.19b), while Creld2 protein levels
are elevated after 30 h and 48 h. Further, Derl3 gene expression is significantly reduced
in the Creld2-/- MEFs after 30–48 h in comparison to Creld2+/+ cells (Figure 4.19b,c).
4.6.2.5 Ire1α pathway regulation during ER stress recovery
In the Ire1α branch, Creld2-/- and wild-type MEFs show similar behaviour after the ER
stress challengen (Figure 4.20). Both, Ire1α gene expression and splicing of Xbp1
(sXbp1) during the recovery phase is increased, and remains at high levels even after
48 h.
Taken together, the results from in vitro ER stress studies reveal reduced cell viability
in Creld2-/- MEFs, which is consistent in both ER stress models. Additionally, Creld2-/-
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Figure 4.18: Regulation of Perk pathway induced components during ER stress recovery.
(a) Gene expression analysis of Perk and Gadd34 in Creld2+/+ (n=10) and Creld2-/- (n=8)
MEFs. Transcriptional induction of these genes is not altered in Creld2-/- fibroblasts compared
to the wild-type controls. (b) Immunoblot analysis and (c) quantification and assessment of
Perk and eIF2α activation by determination of their phosphorylation levels. Protein levels
were normalised to β-Actin and ratios of phosphorylated to unphosphorylated proteins were
determined. Creld2-/- cells show reduced levels of P-Perk and P-eIF2α from the start of the
experiment. Phosphorylation of Perk in Creld2+/+ MEFs peaks at 48 h while it stagnates in
Creld2-/- cells after 6 h. Phosphorylation of eIF2α increases until 10 h and drops to control levels
afterwards in wild-typeMEFs, whereas P-eIF2α levels inCreld2-/- increase slower and reach the
peak at 30 h of the experiment. Coloured circles represent measured MEF clones (Creld2+/+
and Creld2-/-, n=3). Gene expression and protein phosphorylation ratio data are presented as
mean±SD. P-values were calculated using unpaired, two-tailed Student’s t-test.
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Figure 4.19: Regulation of Atf6α pathway induced components. (a) Gene expression
analysis of Atf6α, Creld2 in Creld2+/+ and GFP in Creld2-/-, Edem1 and Derl3 in MEFs (n=10
for Creld2+/+ and n=5–8 for Creld2-/-). Transcriptional induction of Atf6α and Edem1 is not
altered in Creld2-/- fibroblasts compared to the wild-type controls. Gene expression of Creld2 is
induced after 6 h of experiment, while expression ofGFP remains approximately at the baseline
level over the whole time course. Derl3 is significantly reduced in Creld2-/- cells after 30–48h
of experiment. (b-c) Immunoblot analysis (b) and quantification of immunoblots (c) of Creld2
and GFP protein levels. Determination of GFP protein levels was unattainable in Creld2-/- cells
and was omitted in the evaluation. Creld2 protein abundance increases after 30 h and is rising
until the end of the monitoring time. Coloured circles represent individual MEF clones (n=3).
Protein levels were normalized to β-Actin and presented relative to the 0 h controls. Gene
expression and immunoblot analyses are presented as mean±SD. P-values are indicated and
were calculated using unpaired, two-tailed Student’s t-test.
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Figure 4.20: Regulation of the Ire1α pathway during ER stress recovery. Gene expression
analysis of Ire1α and sXbp1 in Creld2+/+ (n=10) and Creld2-/- (n=8) MEFs. Gene expression
is presented relative to the 0 h controls, which were set to 1. Gene expression is presented as
mean±SD.
cells display a late and insufficient response to ER stress during ER stress recovery
as evidenced by UPR dysregulations in the Perk and Atf6α branches. These results
suggest that Creld2 is involved in the regulation at least two UPR branches during ER
stress.
4.7 Identification of Creld2 interaction partners
The general in vivo and in vitro analyses of animals and cells deficient for
Creld2 provides a basic insight into emerging abnormalities due to Creld2 absence.
The observed phenotypes resulting from Creld2 deficiency would suggest Creld2
involvement in profoundly complex processes, for instance, in the metabolism of
carbohydrates and fatty acids and the UPR. To narrow down the potential molecular
function of Creld2, its protein interaction partners were analysed by affinity purification
with subsequent mass spectrometrical identification and quantification of co-purified
proteins. For this purpose, tagged Creld2 constructs were used to co-purify protein
interaction partners. To exclude inhibition of protein binding due to the fused tag,
Creld2 was tagged N- and C-terminally. Furthermore, Creld2 was purified from either
transiently or stably expressing HEK cells to enable distinction between specifically
and unspecifically bound chaperones, since it is known that a strong transient
overexpression increases the co-purification of heat shock proteins (HSPs) [84]. To
reduce unspecific binding and for purification of proteins under native conditions, Creld2
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was fused to the tandem affinity tag comprised of two StrepII and one Flag-tag (SF-tag)
and purified by tandem affinity purification (TAP) according to Gloeckner et al. [54].
The SF-tag was fused to the N- or C-term of Creld2 with the Flag-moiety facing the
N- or C-term, respectively. Purified samples from transiently or stably expressing cells
transfected with a mock vector only containing the SF-tag were included in the analysis
to exclude unspecific binding of proteins to the SF-tag.
Proteins identified by mass spectrometry were analysed by hierarchical clustering of
mean protein intensities co-purified with each condition to visualise general differences
and similarities between all five conditions (Figure 4.21a). Here, it is noticeable
that samples from transiently expressing cells show a different protein profile than
those from stably expressing cells. Furthermore, general differences between
Creld2-containing TAP samples and their respective mock controls can be detected. To
evaluate the three Creld2-containing TAPsamples for common co-sedimented proteins,
enriched proteins in Creld2 pull-down samples were compared and visualised in a
Venn diagram (Figure 4.21b) (for a detailed protein list, which are enriched in each
Creld2-containing TAP sample see Appendix A1). Comparing enriched proteins in
the Creld2-containing TAP sets displays an overlap of all three sets for Creld2 and
Enolase 1 (ENO1). For a better understanding of how the co-purified proteins might be
biologically associated to each other, enriched proteins (Appendix A1) were analysed
for functional interactions to one another using the Reactome pathway database,
which contains manually curated and peer-reviewed protein interaction and pathway
analysis data. Subsequently, proteins were manually separated according to their
main subcellular localisation (Figure 4.21c). Co-purified proteins from virtually every
cell compartment are found enriched in Creld2 TAP samples. Moreover, two-thirds
of these proteins display interconnectivity, leaving one-third of the identified proteins
without mapped interactions due to lacking information on protein interactions in the
Reactome pathway database. In addition, pathway enrichment analysis was performed
to investigate the biological processes of the enriched co-purified proteins (Table 4.1).
Among the top 20 enriched pathways with an FDR≤0.05, pathways involved in glucose
metabolism and the activation of the UPR are present. The potential involvement
of Creld2 in the regulation of these pathways is in line with the observed glucose
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metabolism (Figure 4.5) and UPR pathway regulation (Section 4.6) phenotypes in
Creld2-/- mice and cells, respectively.
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Figure 4.21: Analysis of Creld2 interaction partners. (a)Hierarchical clustering of co-purified
proteins from indicated samples. Clustering was performed on mean protein LFQ intensities
(log2-transformed) from n=3 for each sample condition. (b) Venn diagram of co-purified proteins
enriched in pull downs with tagged Creld2 vs. mock constructs. (c) Reactome analysis and
spatial separation of proteins in (b). Protein nodes with yellow border indicate proteins without
interaction annotation. LFQ: Label-free quantification SF: StrepII-Flag tag; FS: Flag-StrepII
tag; Creld2-SF: C-terminally tagged Creld2; FS-Creld2: N-terminally tagged Creld2; mock:
SF tag control: transient: Purification 72 h post-transfection; stable: Purification from stably
expressing cells.
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Table 4.1: Proteins affiliated to enriched pathways
Reactome Pathway FDR Hit proteins
RMTs methylate histone arginines 0.0115 PRMT5, WDR77,
HIST1H4A
HSF1-dependent transactivation 0.0115 HSP90AB1,
HSP90AA1, HSPA8
TFAP2A acts as a transcriptional repressor during
retinoic acid induced cell differentiation
0,0119 HSPD1, NPM1
Metal sequestration by antimicrobial proteins 0.0119 S100A8, LTF
Glycolysis 0.0144 ENO1, TPI1, GAPDH
Gluconeogenesis 0.0147 ENO1, TPI1, GAPDH
Golgi Associated Vesicle Biogenesis 0.0149 CLTC, TXNDC5,
HSPA8
RNA Polymerase I Promoter Opening 0.0157 HIST2H3A,
HIST1H4A
Gene Silencing by RNA 0.0217 HSP90AA1,
HIST2H3A,
HIST1H4A, RAN
DNAmethylation 0.0217 HIST2H3A,
HIST1H4A
ATF6 (ATF6-alpha) activates chaperone genes 0.0250 HSP90B1, HSPA5
Activated PKN1 stimulates transcription of AR
(androgen receptor) regulated genes KLK2 and KLK3
0.0273 HIST2H3A,
HIST1H4A
SIRT1 negatively regulates rRNA Expression 0.0273 HIST2H3A,
HIST1H4A
HSF1 activation 0.0273 HSP90AB1,
HSP90AA1
ATF6 (ATF6-alpha) activates chaperones 0.0273 HSP90B1, HSPA5
The NLRP3 inflammasome 0.0273 HSP90AB1, TXN
trans-Golgi Network Vesicle Budding 0.0273 CLTC, TXNDC5,
HSPA8
Clathrin derived vesicle budding 0.0273 CLTC, TXNDC5,
HSPA8
Transcriptional regulation by small RNAs 0.0333 HIST2H3A,
HIST1H4A, RAN
Formation of the cornified envelope 0.0375 CASP14, DSG1,
JUP
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5.1 General phenotype of the Creld2-knockout-mouse
Consistent with other studies of the Atf6α pathway, which show that most of Atf6α
downstream targets are dispensable during fetal and postpartal development [85–87],
Creld2 function also does not seem to be relevant for embryonic development, as
evidenced by similar Mendelian distributions of Creld2+/+ and Creld2-/- mice (Figure
4.1a). Additionally, Creld2-/- mice show normal body weight gain during ageing (Figure
4.1b) when compared to wild-type mice and exhibit equal live expectancies asCreld2+/+
littermates. Nevertheless, the liver, which experiences constant ER stress, seems to
require Creld2 function. Despite showing no major differences in body weights, liver
weights of aged, 12-months-old, Creld2-/- mice are significantly reduced (Figure 4.1c)
and Creld2-/- mice also show reduced liver to body weight ratios (Figure 4.1d), although
not significant, which might be accountable to the high variability of measured individual
mice. Histological examination of Creld2-/- mice livers shows that young (1-month-old)
Creld2+/+ and Creld2-/- mice display a healthy liver structure (Figure 4.2a), while circa
75% of aged Creld2-/- mice show accumulation of neutral lipids in hepatocytes with
abnormal GS expression (Figure 4.2b). These results indicate that Creld2 is involved
in metabolic homeostasis of the liver during ageing.
5.2 Metabolic aberrations in the Creld2-knockout-mouse
5.2.1 Gender-specific differences
To assess whether Creld2 deficiency leads to gender-specific phenotypes, metabolic
phenotypes of male and female mice were analysed separately. Even though young
Creld2-/- males do not show any histological signs of steatosis (Figure 4.2a), elevated
levels of FFAs, DAGs, TAGs, cholesterol and cholesteryl esters can already be
observed when compared to age-matched wild-type controls (Figure 4.3a) indicating
that male Creld2-/- mice are prone to steatosis development. Both, histological and
quantitative analysis of livers in 1-year-old Creld2-/- mice show a clear accumulation of
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lipids (Figure 4.2b), which is not observed in littermate controls. The hepatosteatosis in
aged Creld2-/- males is accompanied by dysregulated gene expression of the master
regulator of mitochondrial biogenesis Pgc1α (Figure 4.4a), and Apoc2 and Dgat2,
which are involved in TAG metabolism (Figure 4.4b). Further, Creld2-/- males exhibit
insulin resistance and reduced gene expression of glucose transportersGlut2 andGlut4
(Figure 4.5b,e). Interestingly, 1-year-old female Creld2-/- mice seem to be protected
from liver steatosis, since they neither show any differences in hepatic lipid levels
compared to age-matched wild-type controls (Figure 4.3b), nor do they exhibit drastic
differences in gene expression of metabolic markers (Figure 4.4a-d) or in glucose
metabolism (Figure 4.5e,f).
Gender-specific hormonal regulation differences might explain the lack of liver steatosis
in female mice. It is well known that women entering the menopause or those with
genetic defects in oestrogen production exhibit increased risks of developing liver
steatosis [88, 89], which is also true for mice [90], and that supplementation with
oestrogen protects against metabolic syndrome [91] and improves liver functionality
[92].
Therefore, Creld2-/- female mice are most likely protected against hepatosteatosis due
to the increased production of estrogen. The susceptibility for metabolic imbalances
and the development of liver steatosis in female Creld2-/- mice would potentially
increase on entering the menopause.
The following discussion will focus upon the phenotype of male Creld2-/- mice if not
otherwise mentioned.
5.2.2 NAFLD in Creld2-/- mice
NAFLD and insulin resistance are known to be closely correlated with one another, but
until now it is still uncertain which condition is the cause and which the consequence.
Presumably, both metabolic aberration states can trigger the other one, which is due
to impairment of either the lipid or glucose metabolism evoking insulin resistance or
hepatosteatosis, respectively [93, 94]. This, in turn, creates a vicious cycle leading
to aggravating conditions. To unveil the metabolic dysregulations, which might lead
to insulin resistance and hepatosteatosis in 1-year-old Creld2-/- males, mice were
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analysed for their glucose and lipid metabolism states.
To analyse the systemic glucose metabolism in 1-year-old males, glucose tolerance
tests (GTTs) and insulin tolerance tests (ITTs) were performed, which are suited to
show the metabolic situation of the major glucose up-taking organs, namely skeletal
muscle, liver and adipose tissue. GTTs show a slower glucose clearance from the
blood (Figure 4.5b) and ITTs reveal insulin resistance (Figure 4.5b) in Creld2-/- males.
Since it is known that skeletal muscle is the main site of insulin-stimulated glucose
uptake, followed by adipose tissue [95], these results suggest that Creld2-/- mice show
insulin resistance likely due to impaired glucose uptake in extrahepatic organs, such as
muscle and adipose tissue.
Further evidence, which would support this assumption, is the reduction of Glut2 and
Glut4 gene expression (Figure 4.5e), which indicate a decreased ability of the cell to
take up glucose. Especially the reduction ofGlut4 implicates that the muscle or adipose
tissue is the primary cause of insulin resistance. This is because Glut4 is the main
insulin-driven glucose transporter in myocytes and adipocytes [69].
In addition, the elevated P-Akt/Akt ratio in Creld2-/- livers (Figure 4.5c,d) might be a
compensatory mechanism to increase glucose uptake because activated Akt induces
Glut4 translocation to the plasma membrane [66]. Analysis of skeletal muscle
or adipose tissue insulin resistance combined with gene and protein expression
assessment in these tissues could verify this assumption.
Notably, the impaired glucose influx into adipose tissue leads to an elevated release
of FFAs by adipocytes into the bloodstream. These FFAs are taken up by the liver
and skeletal muscle for, e.g. ATP synthesis via β-oxidation. When the abundance
of FFAs exceeds a certain level, the β-oxidation rate diminishes due to mitochondrial
overload, triggering mitochondrial dysfunction and the accumulation of lipids in these
organs, which eventually results in steatosis and increased insulin resistance [96]. Such
an increased FFA release from adipose tissue under this condition might explain the
elevated FFA levels (Figure 4.3a) and the reduced ATP levels (Figure 4.5f) in livers of
1-year-old Creld2-/- mice.
Unlike adipose tissue, the liver cannot store excess amounts of lipids without
impairment of metabolic processes. Therefore, hepatocytes convert these FFAs to
77
5 Discussion
TAGs for secretion into the bloodstream in very low density lipoproteins (VLDLs). In
conditions of FFA overload, the liver fails to meet the demand of FFA conversion to
TAGs, which results in increased levels of DAGs causing metabolic dysregulations [97].
This suggests that DAGs in Creld2-/- livers (Figure 4.3a) indeed accumulate as a result
of increased FFA influx. Additionally, as mentioned in Section 5.2.1, gene expression
ofApoc2 and Dgat2 (Figure 4.4b) is decreased in Creld2-/- mice, which would affirm the
inability of the liver to process the FFA overflow.
The liver is also the site of cholesterol synthesis with acetyl-CoA as the fundamental
building block. Since the liver is oxidising excess FFAs and each cycle of FFA
β-oxidation produces one acetyl-CoAmolecule, this might cause increased cholesterol
synthesis and accumulation as is observed in livers of agedCreld2-/- mice (Figure 4.3a).
Taken together, assessment of the metabolic Creld2-/- phenotype suggests that Creld2
is a potential genetic risk factor in the development of NAFLD and metabolic syndrome.
The results imply that Creld2-/- mice suffer from skeletal muscle and adipose tissue
insulin resistance, which consequently leads to lipid accumulation and dysregulated
metabolic processes in the liver. Instead of letting the mice age to accumulate more
and more lipids over a long time, one could challenge mice with a high-fat diet. This
could reveal an essential function of Creld2 to ameliorate liver stress caused by excess
lipid influx, especially with regards to a western diet, since obesity and overnutrition are
the leading cause of NAFLD, nowadays.
5.3 Liver injury and inflammation
The accumulation of lipids in hepatocytes for extended periods leads to lipotoxicity,
disturbed signalling pathways and lipid-induced apoptosis [98]. Exacerbation of NAFLD
to further stages accompanied by increased apoptosis of hepatocytes results in
inflammatory responses [99,100]. Since the severity of liver steatosis in Creld2-/- males
cannot be determined by simply assessing liver lipids and glucose metabolism, the
steatosis progression grade was determined by analysing gene expression of markers
mirroring liver health state (Figure 4.6).
To determine imbalances in proliferation and apoptosis the genes Erk1/2 and Dr5 were
assessed. Erk1/2 are kinases belonging to the mitogen-activated protein kinase family
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and, among other functions, play important roles in cell proliferation [71]. Increased
Dr5 gene expression is observed during ER stress-induced apoptosis [22] and is also
correlated to lipotoxicity in liver steatosis [101]. Thus, dysregulated Erk1/2 or Dr5 gene
expression in Creld2-/- mice would indicate pathologic cell fates. Yet, Creld2-/- mice do
not show differences in cell proliferation or apoptosis compared to Creld2+/+ mice as
evidenced by similar gene expression of Erk1/2 and Dr5. Further, gene expression
of the acute phase response markers Apcs and Saa3 remain unchanged (Figure 4.6b)
and expression levels of pro-inflammatory cytokines Tnfα and Il6 are slightly decreased
in Creld2-/- males when compared to littermate controls (Figure 4.6c). This indicates
that Creld2-/- mice rather experience a benign liver steatosis since aggravation of
hepatosteatosis is correlated with increased acute phase response genes as well as
inflammatory cytokines.
The absence of inflammation could be the result of either reduced recruitment of
leukocytes from the bone-marrow to injured liver tissue sites or a deficiency in the
response by Kupffer cells, which are major producers of pro-inflammatory cytokines.
Both processes are essential for the replenishment of tissue-resident macrophages,
which in turn maintain and repair tissue by eliciting pro-inflammatory responses [102,
103]. However, Kupffer cell numbers are unchanged in Creld2-/- males compared to
Creld2+/+ males (Figure 4.7a). Further, BMDMs that would give rise to pro-inflammatory
immune cells in the liver during steatosis [104, 105] were tested for their inflammatory
response to stimulation. LPS stimulation of BMDMs and assessing the gene expression
of pro-inflammatory cytokines Tnfα, Il1β and Il6 reveals proper immune responses in
Creld2-/- BMDMs.
Hence, analyses of liver injury and inflammation states imply that Creld2-/- males still
exhibit a benign form of steatosis.
5.4 Impaired UPR as the trigger of hepatosteatosis
The UPR is a crucial machinery for the maintenance and re-establishment of cellular
homeostasis and activity. Unresolved ER stress leads to attenuation of cellular
processes, directing the cell into apoptosis and consequently impedes organ function.
Besides the three major tasks of halting global protein synthesis, increasing folding
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capacity and enhancing unfolded protein degradation, the UPR reveals more and more
crucial metabolic functions reaching beyond the sole elimination of ER stress. The UPR
receives increasing importance in the regulation of genes involved in lipid metabolism
and is frequently linked to the development of fatty liver during conditions of disturbed
activity in any of the three UPR pathways [15,36,34,16,32].
Creld2 is induced by the Atf6α pathway during ER stress and lack of Creld2 increases
susceptibility for fatty liver development and thus might constitute a connecting element
between UPR regulation and metabolism homeostasis.
However, the mode of function of Creld2 and which pathways are downstream of Creld2
remain enigmatic. Hence, the aim was to unravel whether Creld2 is at the intersection
of metabolism and UPR by contributing to proper regulation of the UPR.
For this purpose, UPR pathways in livers of 1-year-old mice were investigated to test
whether UPR downstream signalling cascades are impaired in Creld2-/- mice (Figure
4.8). The results display similar steady state levels of assessed UPR components,
except for increased gene expression of Grp94 (Figure 4.8a) and slightly reduced
P-eIF2α/ eIF2α ratios (Figure 4.8e,f) in Creld2-/- males. This would imply that ablation
of Creld2 does not affect UPR regulation and that increased Grp94 expression might
be a compensatory mechanism to ameliorate the metabolic phenotype, due to Grp94
involvement in various processes, such as in pancreatic β-cell functionality [106] and
maintenance of liver parenchymal health state [107]. However, some experimental
issues could have masked the results. First, the steatotic phenotype in aged Creld2-/-
males is not 100% penetrant and only observed in circa 75%. This phenotypic
heterogeneity might conceal effects in UPR regulation since analyses of livers were
performed on mice cohorts without a prior histological assessment of steatosis.
Second, UPR analyses in unchallenged livers with only mild steatosis (as discussed
in section 5.3) might not be a proper assessment of UPR regulation, since changes in
the UPR at steady state may be minor or too transient to be revealed.
Therefore, an isolated in vitro system approach was chosen for in-depth analysis
of UPR regulation under various ER stress challenge conditions enabling constant
measurements of cellular and molecular changes. Two conditions, termed chronic ER
stress and ER stress recovery, were applied as an approach to challenge cells while
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mimicking potential stress situations in the liver.
These experimental setups revealed that Creld2-/- MEFs are unable to resolve chronic
stress conditions (Figure 4.11). Also in the recovery model, where a short pulse of
a moderately strong ER stress was evoked with subsequent recovery for five days,
Creld2-/- cells were unable to overcome the challenge and display reduced cell numbers
compared to Creld2+/+ MEFs (Figure 4.16a).
Thus, in contrast to analyses of biologically heterogenous livers, the results from in vitro
experiments strongly indicate a need for Creld2 when cells experience emerging ER
stress.
5.4.1 Chronic ER stress
Analysis of UPR pathways including general ER stress marker during chronic ER
stress, reveals dysregulation of Atf6α downstream target genes Edem1 and Derl3 in
Creld2-/- cells (Figure 4.14a). Both Edem1 and Derl3 are important components of
the ERAD machinery, implying that Creld2-/- cells are unable to properly resolve ER
stress due to deficiencies in degradation of unfolded proteins. However, components
of the Perk and Ire1α pathways and also ER stress markers do not show remarkable
dysregulation of UPR components, which would indicate that Creld2 largely influences
Atf6α downstream targets.
5.4.2 ER stress recovery
In contrast to the chronic ER stress model, Creld2-/- cells analysed during ER stress
recovery exhibit extensive regulatory aberrations in various UPR pathways. Monitoring
of general ER stress marker reveals reduced induction of chaperones Grp78 and
Grp94 (Figure 4.17a), which is indicative for impaired activation of at least one UPR
pathway since these markers are regulated by a combination of two or more UPR
branches. However, Grp78 protein levels, which are elevated already in control (0 h)
Creld2-/- cells until 10 h of the experiment when compared to Creld2+/+ cells (Figure
4.17b,c), indicate that a homogenous cell population deficient for Creld2 undergoes
UPR activation already during steady state conditions. In addition, gene expression
of Dr5 is elevated in Creld2-/- MEFs after 48 h (Figure 4.17a) suggesting that Creld2-/-
cells a more susceptible for ER stress-induced apoptosis, which reflects the observed
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reduction of cell number in Creld2-/- cells left for recovery after 2 h and 4h of Tg
challenge (Figure 4.16a).
In this recovery model, lack of Creld2 further impacts the Perk pathway (Figure 4.18)
as Creld2-/- cells display a reduced and delayed phosphorylation of Perk and eIF2α,
which is indicative for an inefficient and late activation of Perk and subsequent inhibition
of eIF2α (Figure 4.18b,c). Thus, during ER stress, global protein synthesis is not
attenuated immediately in Creld2-/- cells leading to exacerbation of ER stress trough
continuous influx of proteins into the ER, thereby burdening the ER with an abundance
of non-native proteins for processing. Consequently, cells experience ER stress for a
prolonged period, because the ER is overloaded and requires more time to fold and
process the abundant proteins eventually leading to apoptosis.
Furthermore, dysregulated Perk pathway activation likely implicates alteredAtf4 protein
expression. Atf4 was reported to induce expression of pivotal genes for cholesterol
metabolism, while Atf4 deletion results in accumulation of free cholesterol in livers
of knockout mice [34]. Since it is crucial for the cell to esterify free cholesterol for
storage, cholesteryl esters in Creld2-/- male livers (Figure 4.3a) might be increased as
a consequence of esterifying the excess free cholesterol.
These findings indicate that aberrant Atf4 regulation likely causes the increased
cholesterol levels in Creld2-/- males (Figure 4.3a) during ER stress.
Further deficiencies of UPR activation were observed in components regulated by the
Atf6α pathway. Consistent with results obtained in the chronic ER stress model (Figure
4.14a), induction of Derl3 gene expression during ER stress recovery is insufficient
in Creld2-/- MEFs (Figure 4.19a). The coherence of reduced Derl3 induction in both
models suggests that Creld2 is upstream of Derl3 gene expression and possibly also
plays a role in regulating other components of the ERAD machinery.
Derl3 accelerates clearance of the ER from unfolded proteins by re-translocating
non-native glycoproteins from the ER to the cytosol for degradation. Hence, the
insufficient induction ofDerl3would lead to sustained ER stress due to a slower removal
of non-native proteins from the ER.
Combining the reduced Derl3 induction with the simultaneous delay in Perk pathway
activation, thereby causing additional ER overload with non-native protein, would mean
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an even stronger accumulation of ER stress.
To verify increased total protein accumulation in the ER of challenged Creld2-/- cells,
the ER distension could be assessed by electron microscopy [108]. Alternatively, the
total amount of glycoproteins in different cellular fractions could be determined, as this
would give insights on translocation efficiency of non-native glycoproteins since Derl3
is reported to aid in the re-translocation of glycoproteins [109].
Of note, both chronic and recovery models display reduced or almost absent expression
of the GFP reporter (Figure 4.14a,b and Figure 4.19a,b), indicating either loss of
intron-mediated enhancer sequences due to the replacement of the complete Creld2
gene locus with the GFP reporter, or a potential positive feedback loop of Creld2
leading to its own induction. A possible mechanism for this feedback loop might
be enhanced Atf6α shuttling to the Golgi and possibly also its proteolytic cleavage
leading to increased Atf6α transcriptional activity, which could be tested in an in vitro
overexpression model.
In the Ire1α pathway, Creld2-/- cells show similar induction of Ire1α gene expression
and splicing of Xbp1 when compared to wild-type cells (Figure 4.20a), which would
indicate that this pathway is not impaired in its function. However, sXbp1 was found to
dimerise with the active transcription factor Atf6α to induce gene expression of ERAD
components [25]. Further evidence provided by RNA-seq studies show that these two
pathways function synergistically [16] so that the possibility of aberrant Ire1α pathway
function cannot be excluded. Analysing Atf6α nuclear translocalisation together with
RNA-sequencing in challenged Creld2+/+ and Creld2-/- cells could clarify potentially
dysregulated sXbp1 transcriptional activity.
5.4.3 Chronic ER stress versus ER stress recovery
Comparing the two in vitro ER stress models reveals consistent impairments in the
regulation of Atf6α pathway components, suggesting a feed-forward loop influence of
Creld2 on its gene expression and the expression of Derl3. Additional dysregulations
in the Perk branch in the recovery model strongly suggest that Creld2 is involved the
regulation of several UPR branches. Since it is known that the three UPR branches
regulate metabolic processes, these UPR signalling impairments caused by Creld2
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absence might be the trigger of NAFLD in 1-year-old Creld2-/- male mice.
Interestingly, the ER stress recovery model unveils considerably more defects in UPR
activation than the chronic ER stress model. One possible reason might be a masking
effect in the chronic model due to the challenge of cells with too high doses of ER
stressors. Another explanation could be that the duration of ER stress over 48 h-72 h
is inappropriate and fails to mimic physiological states, especially when cells are
challenged by pharmacological ER stressors [110].
Naturally, most organs experience a temporary stimulus of ER stress, e.g. after taking in
a meal or just after awakening, as this results in a rapid increase of metabolic demands,
such as the instant production of large insulin amounts or processing of nutrients by the
liver. Hence, the condition of persistent activation of the UPR might be too artificial and
mostly unphysiological.
What remains uncertain in this study is to which extent Creld2-/- cells are able to adapt
to short but recurring ER stress, since in the recovery model cells were burdened only
with a single transient pulse of ER stress. It would be interesting to investigate UPR
activation and regulation in Creld2-/- cells that have been challenged several times -
in a recurring manner, as one would expect to happen under physiological conditions.
This could give insights and possibly further clarify the development of liver steatosis in
Creld2-/- males. However, evidence from the recovery model point towards a delayed
and insufficient UPR activation, which eventually would lead to accumulation of ER
stress and thereby result in impaired organ function. Thus, the phenotype of Creld2-/-
livers may originate from incomplete resolution of ER stress, which is accumulating with
time, thereby disabling the cells to respond to upcoming ER stress stimuli properly.
5.5 Creld2 in bone development and maintenance
Several studies investigated Creld2 involvement in bone development and growth.
First, Creld2 was found to be upregulated in growth plates of bones suffering from
MCDS [41], a pathophysiological condition caused by collagen X mutation. Other
studies indicate that Creld2 plays a role in proper epiphyseal growth plate development,
whereby Creld2 is suggested to possess PDI activity and to be a component of the
ECM [50,73].
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However, the previous studies did not have the advantage of possessing a knockout
model to study bone formation. Therefore, the epiphyseal growth plate of 1-month-old
Creld2-/- mice was analysed. Indeed, derangements of chondrocytes in the proliferating
zone and increased hypertrophic zone width in Creld2-/- mice compared to Creld2+/+
controls (Figure 4.9a) suggest an important role of Creld2 in chondrocyte differentiation.
However, main characteristics of MCDS are defects in bone growth resulting in mild
dwarfism with short limbs and unbalanced gait [111], which could not be observed
in full Creld2-knockout mice, albeit mice with cartilage-specific deficiency of Creld2-/-
allegedly show retarded growth [73]. The reason for this controversy in observations
remains unclear. However, due to the complexity of a whole organism with a myriad of
metabolic process interactions and cross-talk between diverse organs, the possibility
of a different phenotype in conditional knockout mice compared to a full knockout quite
persists.
Zhang et al. reported that Creld2 augments BMP9-induced osteogenic differentiation
of MSCs leading to enhanced bone formation, while knockdown of Creld2 shows
reduced osteogenic differentiation [51]. Additionally, osteogenic differentiation itself
demands the production of high protein amounts, which automatically leads to ER
stress. Confirming evidence from analyses of Atf6α functionality in MCDS mice shows
an Atf6α-dependent amelioration of disease severity [112], which supports the findings
that Creld2 is upregulated and found in chondrocytes of growth plates during ER stress
conditions.
However, the observations by Zhang and colleagues are contradictory to the findings
in 1-year-old Creld2-/- mice. Here, the bone mineral density is increased in femurs of
aged Creld2-/- males and females when compared to age-matched wild-type controls
(Figure 4.9b,c) indicating the onset of osteopetrosis.
To analyse the severity of increased bone density, the cellularity and abundance of
stem cells were tested, since drastic changes in bone mass may have an impact on
the bone-marrow niche. Creld2-/- mice do not show any deviation in total cell numbers
(Figure 4.10a) nor differences in HSC sub-populations in comparison to Creld2+/+ and
Creld2+/- mice (Figure 4.10d) although Creld2 expression in LSK progenitor cells is
present (Figure 4.10c). This indicates that the osteopetrosis in Creld2-/- femurs is still
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mild since differences in total cell numbers or LSK and HSC populations would be
altered due to a displacement of bone-marrow by over-growing bone in the case of
severe osteopetrosis.
A reason for this discrepancy could be that Zhang et al. do not use genetic models, but
implanted MSCs transfected with murine Creld2 or with Creld2 siRNA so that it is not
clear which effects might be provoked by the absence of Creld2 after extended periods
of time on bone structure.
In summary, all of the reported studies of chondrodysplasia mice models showed
Creld2 upregulation because the disease is mainly induced through unfolded proteins,
which induce ER stress. Despite the discrepancies with previous studies, the results
from Creld2-/- mice suggest that Creld2 plays a role in bone formation, growth and
maintenance by regulating proper UPR pathway activation (as discussed in Section
5.4).
5.6 Creld2 interaction partners
The abnormalities mentioned above in Creld2-/- mice and MEFs suggest that Creld2
is involved in the regulation of metabolic processes and the activation of the UPR.
However, these biological processes are extremely complex, and each is comprised
of numerous pathways involving thousands of proteins cooperating in a myriad of
reactions [113]. Thus, to identify the up- or downstream signalling pathways of Creld2,
its molecular interaction partners were determined.
Creld2 interactome pathway enrichment analysis shows that protein interaction
partners are involved in glucose metabolism and UPR regulation via the Atf6α branch
(Table 4.1). The regulation of these pathways by Creld2, which is consistent with the
metabolic phenotype of Creld2-/- mice (Figures 4.2, 4.3 and 4.5) and the observed
dysregulations in UPR activation (Figures 4.14, 4.17, 4.18 and 4.19).
Evaluation of enriched proteins from Creld2 pull-downs versus their respective mock
controls (Figure 4.21b) shows that the purification from transiently expressing cells
co-precipitates many HSPs and PDIs (Table A1), albeit mean Creld2 abundance
in all Creld2 precipitation conditions is similar. This implies that Creld2 requires
extensive folding aid, thereby drawing chaperones, such as Grp78 (HSPA5), to oneself.
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Conclusively, the attraction of numerous chaperones might result in the activation of
UPR branches, since these chaperones need to dissociate from the ER stress sensors
to assist in the folding of Creld2. In this case, Creld2 would function as a kind of
decoy molecule, which indirectly triggers enhanced UPR activation. This assumption
would be backed up by evidence from previous analyses, which show that a mere
Creld2 overexpression induces gene expression of UPR downstream targets Chop
and sXbp1 after 48 h, although Creld2 protein levels are already increased 24h post
transfection [2].
Additionally, the idea of Creld2 being a decoy protein would be supported by
the obtained results from ER stress recovery experiments, which show delayed
phosphorylation of Perk and eIF2α, and hence a late activation of the Perk downstream
signalling cascade (Figure 4.18c) as well as insufficient induction of Derl3 gene
expression (Figure 4.19a). The native Creld2 proteins residing in the ER might unfold
during emerging ER stress resulting in chaperone attraction. The reason of Creld2
unfolding may be due to the shift from an oxidising to a reducing ER milieu [114] as a
consequence of ROS production [115], which would lead to the reduction of disulfide
bonds in the EGF-like domains of Creld2 (see structure in Figure 1.1).
Another mode of function of Creld2 to augment UPR activation might be to enhance the
secretion of chaperones, such as Grp78 or HSPs in general. Creld2 is a glycoprotein
[10, 2] and can be secreted [8, 50]. Likewise, Grp78 was found to be translocated to
the plasma membrane [116], especially during ER stress [117], where it regulates and
favours proliferation and cell survival [118,119]. This would suggest that Creld2 might
also serve as a protein shuttling guide for numerous chaperones and ECM proteins
since several HSPs and ECM proteins were identified as Creld2 co-precipitates (Figure
4.21c). Increased Grp78 shuttling to the plasmamembrane would consequently reduce
Grp78 abundance in the ER, leading to less Grp78 for inactivation of the three ER stress
sensors.
Taken together, these results suggest that Creld2 might function as a decoy molecule,
sequestrating HSPs, such as Grp78 (HSPA5), from the ER stress sensors due to its
folding needs and thereby leads to enhanced activation of the UPR.
Further analysis of proteins enriched in Creld2 pull-downs (Figure 4.21b) revealed
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the presence of ENO1 in all three Creld2 pull-down conditions (Table A1). ENO1 is
a glycolytic enzyme involved in the break down of glucose to pyruvate [120] and is
reported to take part in numerous other cellular processes, such as immune responses
and development [121]. In addition, pull-down from stably expressing cells show
common enrichment of two further proteins involved in glucose metabolism, namely
lactate dehydrogenase (LDH) A and LDHB. LDHA converts pyruvate to lactate and is
not affected by substrate or product inhibition, while LDHB reverses this reaction and
is inhibited by high pyruvate concentrations [122].
Taking into account that Creld2-/- males exhibit liver steatosis (Figure 4.2b, Figure 4.3),
insulin resistance (Figure 4.5b) and decreased ATP levels (Figure 4.5f), the interaction
of Creld2 with enzymes involved in glucose metabolism strongly suggests that Creld2
additionally plays a role in regulation of glucose processing.
To clarify whether Creld2 influences carbohydrate metabolism via regulating of ENO1
and LDHA/LDHB activity, biochemical assays for the determination of glycolysis and
pyruvate conversion rates in Creld2+/+ and Creld2-/- liver lysates could be performed.
In summary, Creld2 co-purification results further affirm that Creld2 most probably is
involved in the regulation of metabolic processes and enhancement of UPR activation
and thereby helps in maintaining metabolic homeostasis in an organism.
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5.7 Conclusion
The present study reveals new insights into the function of Creld2 in an organism
and its role in the orchestration of the UPR. Creld2-/- mice reveal susceptibility to
the development of a benign liver steatosis accompanied by insulin resistance and
dysregulation of genes involved in glucose and lipid metabolism. These findings render
Creld2 as a novel genetic risk factor for the development of NAFLD and metabolic
syndrome. The general phenotypic observations probably are the consequence of the
incapability of cells to cope with ER stress. This is evidenced by in vitro analyses of
UPR regulation, which imply that Creld2 is involved in the orchestration of a prompt and
robust response to ER stress. Here, the loss of Creld2 results in a delayed attenuation
of global protein synthesis and an insufficient induction of important components for
protein degradation. Cues obtained by protein interaction studies suggest that under
ER stress conditions, Creld2 is bound by chaperones, which triggers activation of the
UPR. On top of that, Creld2 co-precipitated proteins, such as ENO1 and LDHA/LDHB,
suggest that Creld2 additionally is involved in carbohydrate metabolism.
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6 Summary
The aim of this thesis was to investigate the role of Creld2 in the maintenance of
metabolic homeostasis under steady state conditions and in the regulation of the
UPR under ER stress conditions. Metabolic analyses of Creld2-/- mice revealed a
susceptibility of 1-year-old males for the development of hepatosteatosis and insulin
resistance, accompanied with dysregulated gene expression of Pgc1α, and a reduced
gene expression of the glucose transporters Glut2 and Glut4. Female Creld2-/- mice
were protected from liver steatosis probably due to gender-specific hormonal regulation
differences. In vitro ER stress analyses of wild-type and Creld2-deficient MEFs showed
that Creld2-/- cells cannot tolerate the emerging stress as well as Creld2+/+ cells and
consequently become apoptotic when challenged with ER stress. In-depth analyses
of the three UPR branches displayed a delayed and deficient response to ER stress,
which leads to incomplete ER stress relief and to ER-stress accumulation rendering
the cells dysfunctional. These in vitro results support the hypothesis that lack of Creld2
results in unresolved ER stress and the subsequent development of liver steatosis. In
addition, Creld2 co-precipitation studies reveal an enrichment of numerous chaperones
and proteins involved in carbohydrate metabolism, which indicates that Creld2 may
bind to and effect the function of these proteins. Concluding, the results of this thesis
suggest that Creld2 is involved in the regulation of metabolic processes by enhancing
and orchestrating the UPR to enable proper ER stress resolution.
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